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Review
Molecular Methods and Platforms for Infectious
Diseases Testing
A Review of FDA-Approved and Cleared Assays

Rajyasree Emmadi,* Jerry B. Boonyaratanakornkit,†
Rangaraj Selvarangan,‡ Venkatakrishna Shyamala,§
Barbara L. Zimmer,¶ Laurina Williams,储 Bonita Bryant,**
Ted Schutzbank,†† Michele M. Schoonmaker,‡‡
Jean A. Amos Wilson,§§ Leslie Hall,¶¶ Preeti Pancholi,储储
and Kathryn Bernard***

wide variety of common pathogens. The information
presented in this review will be particularly useful for
laboratories that plan to implement or expand their
molecular offerings in the near term. ( J Mol Diagn
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In 1986, the Food and Drug Administration (FDA) approved the first nucleic acid test, the DNA probe for
identification of Legionnaires’ disease from bacterial
culture, marketed by Gen-Probe Inc. (San Diego, CA).1
Seven years later, the FDA cleared the AMPLICOR CT
test (Roche Molecular Systems, Branchburg, NJ), the
first DNA amplification-based test for detection of Chlamydia trachomatis (CT) directly from a clinical sample.2
Since then, the field of clinical molecular testing in
infectious diseases has grown enormously; it represents approximately 70% of the global molecular testing market.3
The FDA regulates in vitro diagnostic devices (IVDs),
which include the reagents, systems, and products used
in the molecular diagnostic assays as class I, II, or III
medical devices, with increasing regulatory oversight, to
ensure safety and effectiveness according to the risk

The superior sensitivity and specificity associated
with the use of molecular assays has greatly improved
the field of infectious disease diagnostics by providing clinicians with results that are both accurate and
rapidly obtained. Herein, we review molecularly
based infectious disease diagnostic tests that are Food
and Drug Administration approved or cleared and
commercially available in the United States as of December 31, 2010. We describe specific assays and their
performance, as stated in the Food and Drug Administration’s Summary of Safety and Effectiveness Data
or the Office of In Vitro Diagnostic Device Evaluation
and Safety’s decision summaries, product inserts, or
peer-reviewed literature. We summarize indications
for testing, limitations, and challenges related to implementation in a clinical laboratory setting for a
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posed to the patient if the results are incorrect. Several
specific guidance documents regarding the classification and review criteria of these tests are available from
the FDA Medical Devices website (http://www.fda.gov/
MedicalDevices/default.htm, last accessed December 31,
2010). The FDA also determines test complexity as high,
moderate, or waived, with most molecular IVDs being
designated as high-complexity tests. The term FDA
cleared is used for assays that are routed by a 510(k),
submission showing substantial equivalence to any assay already cleared by the FDA or marketed before 1976.
The term FDA approved is used when an assay is routed
by a premarket approval application to demonstrate its
efficacy and safety. A searchable database of FDA-approved or FDA-cleared assays can be accessed (http://
www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/
pmn.cfm, last accessed December 31, 2010), and an
updated list of FDA-cleared assays is available at the
Association for Molecular Pathology website (http://
www.amp.org/FDATable/FDATable.doc, last accessed
December 31, 2010).
Molecular infectious disease (MID) testing offers
several advantages, including rapid test results facilitating detection of outbreaks and, in some cases,
newly emerging strains; and sensitivity, specificity,
identification of resistant organisms, and quantifiable
correlation to disease severity, all of which contribute
to timely therapeutic clinical decisions and early infection control interventions.4 Multiplex methods can simultaneously detect multiple infectious agents in a single clinical specimen. In addition, these methods are
able to identify organisms that may be difficult to isolate or have not been cultured by traditional methods.
Assays that provide sequence or genotype can trigger
collection of epidemiological information, track disease
outbreaks, provide strain resistance data and/or treatment prognosis, and determine the method or source
and means of spread of infection.
This review complements a new Clinical and Laboratory Standards Institute guideline, MM19: Establishing
Molecular Testing in Clinical Laboratory Environments,
under review at the time of this article’s submission (Leslie Hall, personal communication in June 2011). The assays described were selected by reviews of several databases, including the FDA database, the Association for
Molecular Pathology website, and the PubMed database
for publications related to MIDs. Although we have attempted to provide a comprehensive review of commercially available FDA-cleared or FDA-approved IVDs and
platforms, we do not endorse or promote any one of these
over the other. Our review is limited to FDA-cleared or
FDA-approved assays available in the US market as of
December 31, 2010. Esoteric assays, such as those for
bioterrorism agents and emergency use, are beyond the
scope of this review. However, additional information can
be obtained at the CDC and FDA websites (http://
www.selectagents.gov/index.html and http://www.fda.gov/
MedicalDevices/Safety/EmergencySituations/ucm161496.
htm, respectively; last accessed December 31, 2010).

Specific Considerations for Commercially
Available MID Assays
We focus on commonly used assays and relevant information to assist the molecular laboratory director in assay
selection and implementation. Assays available for diagnosis and treatment are presented herein in four groups:
sexually transmitted diseases (STDs) (Table 1), health
care–associated infections (HAIs) and surveillance (Table 2), respiratory tract and central nervous system (CNS,
Washington, DC) infections (Table 3), and other infections and culture confirmations [eg, hepatitis B virus
(HBV), various cultures, and ancillary assays for HAI and
surveillance] (Table 4). For each area, we highlight several MID assays; and reference to additional FDA-cleared
assays is found in Tables 1– 4.
During the FDA IVD review process, each MID assay
described in the specific product insert is approved or
cleared for a specific patient population, specimen type,
and extraction method. If a laboratory chooses to deviate
from the product insert (eg, to offer a specimen type that
is not described in the product insert), the modified assay
is considered off-label use and the laboratory is obligated
to perform a thorough validation to ensure that the modification does not alter performance claims. We present
assay sensitivity, specificity, limit of detection, dynamic
range, and percentage positive or negative agreement
with culture results, as applicable.
It is out of the scope of this article to describe the
actual process of implementation of MID testing; however, there are several excellent recent references5,6 to
assist the laboratory.

STD Data
HPV Data
More than 100 genotypes of human papilloma virus
(HPV) (Table 1) have been identified based on DNA
sequence heterogeneity, and ⬎40 of these infect anogenital or ororespiratory tracts. HPV genotypes have
been divided into four oncogenic risk classes: low, intermediate/high, high, and unknown. The World Health Organization’s International Agency for Research on Cancer (IARC), in 2009, classified HPV-16, HPV-18, HPV-31,
HPV-33, HPV-35, HPV-39, HPV-45, HPV-51, HPV-52,
HPV-56, HPV-58, and HPV-59 as high-risk (hr) HPV types
with sufficient evidence for causing cervical cancer, with
special emphasis on HPV-16 as being the most aggressive type.7 Periodically, the IARC has revised its listing of
hr-HPV, and the components of the list have varied.
One prevailing viewpoint finds HPV testing differs from
other molecular assays in that analytic sensitivity for detection of HPV is not the prime driver of assay performance. A high analytic sensitivity can decrease the clinical specificity, resulting in more false referrals for
colposcopy and biopsy, decreased correlation with histological presence of disease, and a consequent distrust
of a positive result by the treating physician.8 This approach was further emphasized by Meijer et al,9 who set
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forth requirements for a candidate HPV screening molecular assay. A historical review of the use of HPV testing in
the screening and management of abnormal cervical
screening results is provided in a recent article by Cox,10
and we recommend reading this as part of a molecular
laboratory director’s preparation for the introduction of
HPV testing. Although some commercially available HPV
assays target both low-risk and hr-HPV types, we limit our
discussion to the application of assays detecting hr-HPV
(Table 1 contains a complete listing).
The Digene Hybrid Capture 2 (HC2) HPV DNA Test
(Qiagen, Gaithersburg, MD) has been the most widely
used molecular HPV assay in most clinical trials and has
been extensively reviewed.11 This assay is FDA approved for triage in cases of equivocal cytology results in
the presence of atypical squamous cells of undetermined
significance to determine which patients should be referred for a colposcopy and also as a screening test for
use in addition to cytology in women ⱖ30 years. The
National Cancer Institute–sponsored clinical trial of Atypical Squamous Cells of Undetermined Significance and
Low-Grade Squamous Intraepithelial Lesion Triage Study
and the Canadian Cervical Cancer Screening Trial demonstrated the assay’s greater accuracy compared with
cytology alone in detecting histologically confirmed cervical intraepithelial neoplasia 2/3 lesions of the cervix.12
However, Kitchener et al13 found that liquid-based cytology appears to be closing this gap and may have an
improved sensitivity over conventional cytology.
The HC2 assay uses unlabeled single-stranded fullgenomic-length RNA probes specific for all of the types
recommended by IARC-2009 with the addition of HPV68. The RNA:DNA hybrids are detected by a microplate
chemiluminescent signal amplification method. The use
of full-genome probes prevents false negatives resulting
from gene deletions. The HC2 assay lacks an internal
control to evaluate sample adequacy or the presence of
interfering substances. This assay has a false-positive
rate of 7.8% for detection of hr-HPV because of the crossreactivity with many untargeted low-risk HPV types.14 In
an attempt to demarcate these cross-reactive false positives, which usually show a weak reaction/signal, several
groups recommended a readjustment of the cutoff value
or retesting of initial borderline samples. In 2006, the
concept of an HC2 gray zone was introduced with the
recommendation of retesting repeatedly borderline samples (relative light unit per cutoff of 1.0 to 2.5) by a
different HPV assay having a high analytic specificity.
The manufacturer subsequently changed (only slightly)
the criteria for interpretation of positive results, restricted
to samples collected in ThinPrep PreservCyt solution (Hologic Inc., Bedford, MA) and not applicable to those
collected in the Digene Specimen Transport Medium
(Qiagen Inc., Valencia, CA). The Digene-recommended
algorithm for low-positive HPV results (gray or retest
zone) required a retest followed by a second retest if the
result of the first retest was ⬍1.0 relative light unit per
cutoff. This algorithm was evaluated by Muldrew et al,15
who showed that although retesting of an initial gray zone
sample was necessary, a second retest did not offer
advantages over the first retest. Another group16 showed

that increasing the HC2 positive cutoff value to 2.0 relative light unit would improve clinical specificity, with only
a minimal reduction in clinical sensitivity. However, these
recommendations are not part of the FDA approval of this
assay.
The Cervista HPV HR (Hologic, Inc., Bedford, MA)
assay uses manual extraction with a single-well Invader
Biplex technology format that simultaneously detects
HPV and a Histone H2be DNA internal control in the same
reaction. The assay is an isothermal signal amplification
method using Invader chemistry. The probe pools detect
14 HPV types (IARC-2009 12 hr-HPV plus HPV-66 and
HPV-68) and identify type-specific single-nucleotide
polymorphisms, effectively decreasing cross-reactivity
with low-risk types and false-positive results. The assay
only requires 2.0 mL of sample (half the requirement of
Digene HC2). The inclusion of an internal control is a
quality control measure that differentiates between a true
negative and a sample with insufficient DNA present and
is also a verification of the procedure. The same sample
specimen used in the Cervista HPV HR may then be
reflexed to the Cervista HPV 16/18 genotyping assay,
which specifically identifies the presence of HPV types 16
and 18, now implicated in approximately 70% of cases
progressing to cancer.17,18
In a postapproval clinical study (SHENCCAST II, conducted in China) comparing the HC2 with the Cervista
hr-HPV assays, the HC2 showed better sensitivity (95.6%
versus 92.9%), whereas the Cervista assay demonstrated a statistically significantly higher specificity
(91.1% versus 88.6%; P ⬍ 0.05).19
HPV testing is performed predominantly on liquidbased cytology samples, and sample collection is determined by the method in use. The HC2 assay has been
validated for use with the Digene Specimen Transport
Medium and the ThinPrep PreservCyt solution. Use of
other collection media (eg, SurePath liquid cytology medium) is considered unapproved off-label use. The Cervista assay has been validated for use with the PreservCyt
solution. The typical turnaround time is 1 to 3 days, depending on the platform and availability of automation.
In addition to molecular assays for the detection of
HPV, the FDA has also approved the Cervista HPV 16/18
genotyping assay, briefly mentioned earlier (Hologic,
Inc.). This assay is based on the same Invader technology as the Cervista hr-HPV detection test and, as indicated by its name, specifically detects and distinguishes
HPV types 16 and 18. For cytology-negative, hr-HPV–
positive women, HPV 16/18 genotyping can be used to
determine who should be referred for immediate colposcopy. If the HPV 16/18 genotyping test result is negative,
then cytology and hr-HPV testing are recommended to
be repeated in 12 months. The American Society for
Colposcopy and Cervical Pathology Consensus Conference Recommendations for HPV 16/18 detection do not
recommend the use of HPV genotyping in women with
atypical squamous cells of undetermined significance
who test positive for hr-HPV. Alternatively, the American
Society for Colposcopy and Cervical Pathology recommends that these women are referred to colposcopy
(American Society for Colposcopy and Cervical Pathol-
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Table 1.

STD Assays

Organism
HPV

HSV

CT

NG
NG

Specimen/sample type

Assay/platform (FDA no.)

Cervical cytology specimen in ThinPrep PreservCyt and cervical
cytology specimen in Specimen Transport Medium

Digene HC2 HPV DNA Test (P890064/S006)†

Cervical cytology specimen in ThinPrep PreservCyt and cervical
cytology specimen in Specimen Transport Medium

Digene HC2 High-Risk HPV DNA typing kit
(P890064/S009)†

Cervical cytology specimen in ThinPrep PreservCyt

Cervista HPV HR (P080014)¶

Cervical cytology specimen in ThinPrep PreservCyt

Cervista HPV 16/18 (P080015)¶

Vaginal lesion swab only (not for prenatal screening or in
females ⬍18 years); collected in Copan Universal
Transport Medium or identical Copan- manufactured
media formulation; an extractable sample processing
control target is added to the specimen before lysis

MultiCode RTx HSV 1&2 Kit (K100336)††

Endocervical (female) and urethral (male) swabs; urine
specimens (male and female); gynecological specimens
collected in BD SurePath preservative fluid
Endocervical and vaginal (female) and urethral (male)
swabs; urine specimens (male and female); patientcollected vaginal swab specimen is also accepted
Specimen that has been processed and tested positive by
PACE 2 system for CT
Digene Cervical Sampler or Dacron swab placed in Digene
Specimen Transport Medium

MagNA Pure LC Total NA Kit and Magna
Pure Instrument LightCycler 1.2‡‡
BD ProbeTec CT Qx Amplified DNA Assay
(K090824, K091724, K081824)§§
APTIMA Assay for Chlamydia trachomatis
(K043072, K053446, K061413, K063451)¶¶
PACE 2 CT (K920302)¶¶
Digene HC2 CT-ID DNA Test (K990023,
K010892)†

Endocervical (female) and urethral (male) swabs; urine
specimens (male and female)
Cervical and vaginal (female) and urethral (male) swabs;
urine (male and female); PreservCyt specimens; Surepath
specimens
Vaginal and cervical swabs; urethral swabs (male); urine
(male and female); PreservCyt specimen
Specimen that has been processed and tested positive by
PACE 2 system for NG
Cervical specimens collected using Digene Cervical
Sampler and Digene Swab Specimen Collection kit

COBAS AMPLICOR (CT/NG) Test (K973707,
K973718, K070174, K053287)‡‡
BD ProbeTec GC QX Amplified DNA Assay
(K081825, K090971)§§

Cervical (female) and urethral (male) swabs; urine (male)

AMPLICOR CT-NG for NG (K974503,
K974342, K070172, K053289)‡‡
RealTime CT-NG assay (K092704,
K080739)***
BD ProbeTec ET CT-GC (K012351)§§

CT-NG combined Vaginal (female) and urethral (male) swabs; urine (male and
female); patient-collected vaginal swab specimen
Endocervical (female) and urethral (male) swabs; urine
specimens (male and female)
CT-NG combined Endocervical (female) and urethral (male) swabs; urine
specimens (male and female)
Endocervical (female) and urethral (male) swab specimens
collected with the PACE Specimen Collection kits
Cervical specimens collected using Digene HC2 DNA
Collection Device or Digene Female Swab Specimen
Collection Kit
HIV-1
Human plasma specimens (ACD-A and EDTA)

APTIMA Assay for NG (K043144, K061509,
K062440, K063664)¶¶
PACE 2 NG (K920301)¶¶
Digene HC2 GC-ID DNA Test (K981485,
K010893)†

APTIMA COMBO 2 (K003395, K022874,
K032554, K043224, K060652)¶¶
PACE 2C CT-NG (K940979)¶¶
Digene HC2 CT/GC Dual DNA Test
(K981567, K010891)†,†††
RealTime HIV-1 assay (BP060002)*** and
m2000 (m2000sp ⫹ 2000rt)
(table continues)
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Table 1.

Continued
Linear range (%)*
Method

Hybridization protection assay with signal
amplification using microplate
chemiluminescence hybrid capture of
RNA-DNA hybrid
Hybridization protection assay with signal
amplification using microplate
chemiluminescence hybrid capture of
RNA-DNA hybrid
Invader technology

Invader technology

Real-time PCR using isoC:isoG synthetic
DNA bp technology

Target
RNA probe cocktail for 13 hr
types (16, 18, 31, 33, 35, 39,
45, 51, 52, 56, 58, 59, and
68) and 5 low-risk types (6,
11, 42, 43, and 44)
RNA probe cocktail to detect
13 hr-HPV types (16, 18, 31,
33, 35, 39, 45, 51, 52, 56,
58, 59, and 68)§
E6/E7/L1; cocktail of 14 hrHPV DNA probes (16, 18,
31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68)储;
human histone 2 gene
(internal control)
Cocktail of two types of
sequence-specific DNA
probes**; human histone 2
gene (internal control)
Glycoprotein gene segment
of HSV-1 and HSV-2

Sensitivity

Specificity

‡

61.1

93.0‡

61.1

93.0

92.8

67.2 (aged ⱖ30
years)

PPA, 85.7 (65.4–95.0)

NPA, 95.9 (94.9–96.7)

HSV-1, 92.4

HSV-1, 98.3

HSV-2, 95.2

HSV-2, 93.6

Strand displacement amplification

Alternate region of the
cryptic plasmid

94.5

98.9

Transcription-mediated amplification

23S rRNA

95.6

98.8

Probe competition assay; CT confirmation
test
Hybrid capture

23S rRNA

91.7

98.5

92.3–97.7储储

98.2–98.6储储

92.9–94.1

94.7–98.4

PCR

RNA probe cocktail
complementary to CT
genomic DNA; cryptic
plasmid
Cryptic plasmid

Strand displacement amplification

Pilin gene

99.3

99.4

Transcription-mediated amplification

16S rRNA

92.3

99.8

Probe competition assay; GC
confirmation test
Hybrid capture

rRNA

95.1

98.7

92.6–95.2储储

98.5–98.9储储

95.9–96.5

98.7–97.3

CT, 92.5–97.8
NG, 87.0–100
CT, 92.0
GC, 96.1
CT, 95.2–96.5
NG, 96.5–99.1
CT-NG, 96.8

CT, 98.3–99.8
NG, 99.3–100
CT, 94.9
GC, 98.2
CT, 97.6–98.7
NG, 98.4–99.4
CT-NG, 93.6
CT, 98.7
GC, 99.1

Probe competition assay

RNA probe cocktail
complementary 0.5% of
the NG genome, cryptic
plasmid
M.NgoPII putative methyl
transferase gene of NG
CT, cryptic plasmid
NG, Opa gene
CT, cryptic plasmid
GC, Pilin gene
CT, 23S rRNA
NG, 16S rRNA
rRNA

Hybrid capture

CT-GC RNA probe cocktail

CT, 96.1
GC, 93.0

Real-time RT-PCR

Integrase region in pol gene

40–10,000,000
copies/mL (HIV-1
groups M, N, and O)

PCR
Real-time PCR
Strand displacement amplification
Transcription-mediated amplification

(table continues)
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Table 1.

Continued

Organism

Specimen/sample type

Assay/platform (FDA no.)

Plasma extracted from blood collected using EDTA or
ACD‡‡‡
Plasma separated from blood collected using EDTA
HIV-1

Plasma extracted from blood collected using EDTA or
ACD‡‡‡
Plasma or serum
Plasma or serum
Plasma or serum

HIV-1 drug
resistance¶¶¶

Plasma samples from blood collected in EDTA

Plasma samples from blood collected using ACD or EDTA
anticoagulants

AMPLICOR HIV-1 MONITOR test, version 1.5
(BP950005/4)‡‡ and COBAS AMPLICOR
HIV-1 MONITOR test, version 1.5
(BP950005)‡‡
COBAS AmpliPrep/COBAS TaqMan HIV-1
test (BP050069/0)‡‡ and COBAS
AmpliPrep/COBAS TaqMan‡‡
VERSANT HIV-1 RNA 3.0 Assay (bDNA)
(BP000028/0)§§§ and VERSANT Molecular
System§§§
APTIMA HIV RNA Qualitative Assay
(BL103966/5040)¶¶
Procleix ULTRIO Assay¶¶
Procleix HIV-1, HCV, and/or HBV
Discriminatory Assays (BL 125113/33)¶¶
COBAS AmpliScreen HIV-1 Test (BL 125059/
37)‡‡
ViroSeq HIV-1 Genotyping System
(BK030033)储储储 and ABI 3100/3130 capillary
electrophoresis platform****
TRUGENE HIV-1 Genotyping Kit
(BK090077)§§§ and OpenGene DNA
Sequencing System§§§
(table continues)

*Sensitivity, specificity, linear range, and percentage positive or negative agreement with culture data are sourced from FDA submission material or product inserts.
†
Obtained from Qiagen, Gaithersburg, MD.
‡
Atypical squamous cells of undetermined significance referral Papanicolaou stain population, Kaiser Study, PreservCyt solution specimens.
§
Cross-reacts with HPV types 40, 53, and 66.
¶
Obtained from Hologic, Madison, WI.
储
Cross-reacts with HPV types 67 and 70.
**Cross-reacts with high levels of HPV type 31.
††
Obtained from EraGen Biosciences, Madison, WI.
‡‡
Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
§§
Obtained from BD Diagnostics, Sparks, MD.
¶¶
Obtained from Gen-Probe, Inc., San Diego, CA.
储储
Depending on brush or swab specimens.
***Obtained from Abbott Molecular, Inc., Des Plaines, IL.
†††
This assay is indicated for use as an initial test and requires confirmation with the individual MID assays.
‡‡‡
ACD specimens will yield approximately 15% lower test results because of the dilution effect of 1.5 mL ACD in the collection tube.
§§§
Obtained from Siemens Healthcare Diagnostics, Deerfield, IL.
¶¶¶
Provides information on resistance to nucleoside and nonnucleoside reverse transcriptase and protease inhibitors.
储储储
Obtained from Celera Diagnostics, Alameda, CA.
****Obtained from Applied Biosystems, Foster City, CA.
ACD-A, anticoagulant citrate dextrose solution A; bDNA, branched DNA; NPA, negative predictive accuracy; PPA, positive predictive accuracy.

ogy, HPV Genotyping Clinical Update, http://www.
asccp.org/pdfs/consensus/clinical_update_20090408.pdf,
last accessed December 31, 2010).

CT and NG Data
CT and Neisseria gonorrhoeae (NG) are the most common
cause of bacterial STDs, and both can cause urogenital
tract infections ranging from acute to asymptomatic disease. CT is an obligate intracellular bacterium comprising 15 serovars, whereas NG is a fastidious intracellular
diplococcus. Significant underreporting of disease can
occur as the result of silent infections affecting the reproductive age group. Identification and treatment is important to prevent the sequelae of infection, such as infertility, chronic pain, and pelvic inflammatory disease.
Urogenital specimens commonly exhibit amplification
inhibition. The inhibitory substances can be removed by

including nucleic acid purification steps in the sample
preparation. The sample preparation protocols vary
among the commercially available assays, ranging from
the use of crude lysates (AMPLICOR) to purified nucleic
acids. The Roche AMPLICOR assay uses an amplification control in the sample that allows for detection of
inhibitory substances. This control consists of a plasmidcontaining CT primer binding sites and a randomized
internal sequence. The BD ProbeTec (BD Diagnostics,
Sparks, MD) uses 1000 copies of a linearized NG DNA
containing plasmid as the internal amplification control.
Commercially available assays for CT and NG (Table
1) use target amplification methods, with the one exception being the Digene HC2 assay, which uses a signal
amplification method with an RNA probe cocktail complementary to approximately 39,300 bp (4%) of the Chlamydia genomic DNA and one probe complementary to
100% of the cryptic plasmid. Nucleic acid amplification
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Table 1.

Continued
Linear range (%)*
Method

Target

Sensitivity

Specificity

End point RT-PCR

142 bp in highly conserved
region of Gag gene

Standard, 400–750,0000 copies/mL;
ultrasensitive, 50–100,000 copies/mL (HIV-1
group M)

Real-time RT-PCR

Gag gene

48–10,000,000 copies/mL (HIV-1 group M)

bDNA technology

Pol gene

75–500,000 copies/mL (HIV-1 groups M and O)

Transcription-mediated amplification

Highly conserved regions of
HIV-1 RNA
Highly conserved regions of
HIV-1 RNA, HCV RNA,
and HBV DNA
Gag gene

Transcription-mediated amplification
RT-PCR
RT-PCR, population sequence analysis

RT-PCR, population sequence analysis

HIV-1 subtype B protease
gene and partial
sequence of the reverse
transcriptase regions of
the pol gene
protease gene and part of
the reverse transcriptase
regions

testing assays typically increase sensitivity by targeting
multiple copy genes or plasmids. For CT, the targets
include cryptic plasmid DNA present in nearly all serovars (5 to 10 copies), genes such as omp1, and ribosomal RNA (rRNA; 16S and 23S). For NG, targets include
the cytosine methyl transferase gene (M.NgoPII), the Opa
gene, Piv-1 genes, and 16S and 23S rRNA. The specimen type approved for CT and NG testing is assay specific (Table 1) and includes urethral swab and urine for
males and endocervical/cervical samples, vaginal
swabs, urine, and PreservCyt (Hologic, Inc.) specimens
for females. A male first-void urine specimen and vaginal
swabs are considered optimal specimens, according to
the Association of Public Health Laboratories (http://
www.aphl.org/aphlprograms/infectious/std/documents/
ctgclabguidelinesmeetingreport.pdf, last accessed December 31, 2010).

100
100 (ULTRIO)
100 (HIV-1
discriminatory)
96.5–98

99.83
99.5 (ULTRIO)
99.7–100 (HIV-1
discriminatory)
98.9–99.7

Validated for detection of drug-resistance
mutations in 40 of 60 mutant/wild-type mixture
samples with a viral load range of
2000–750,000 copies/mL
Requires samples with viral loads ⱖ1000
copies/mL

The AMPLICOR NG detection kit (Roche Molecular
Diagnostics, Pleasanton, CA) targets the M.NgoPII gene,
whereas the BD ProbeTec ET CT/GC targets the cryptic
plasmid of CT and the Piv-1 gene of NG. Both of these
assays have cross-reactivity with some Neisseria species.
Confirmatory testing using a different gene target is an
option in such instances. Cross-reactivity has not been
reported for the Real Time CT/NG (Abbott Laboratories,
Des Plaines, IL), APTIMA COMBO 2 (Gen-Probe Inc., San
Diego, CA), and PACE 2 (Gen-Probe Inc.) assays.20
Coinfection with CT and NG occurs in many patients.
Simultaneous detection of both organisms in a single test
is achieved by several assays (Table 1). The APTIMA
COMBO 2 is a second-generation assay that uses target
capture with transcription-mediated amplification and
chemiluminescent hybridization protection. In contrast to
PCR and strand displacement assays, which amplify
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Table 2.

HAI Assays

Organism

Specimen/sample
type

Assay/platform
(FDA no.)

Method

MRSA/SA
Lesion (skin/soft Xpert MRSA/SA Real-time
(screening,
tissue) double
SSTI
PCR
surveillance) swab
(K080837)†
and
GeneXpert
System†
Nasal swabs
(surveillance)

Xpert MRSA
(K070462)†
and
GeneXpert
System†
Nasal swabs
BD GeneOhm
(surveillance)
MRSA ACP
(K093346)‡
and
SmartCycler†
Nasal swabs
Xpert SA Nasal
(presurgical
Complete
screen)
(K100822)†
and
GeneXpert
System†
Nasal swabs
LightCycler
(surveillance)
MRSA
Advanced
test
(K091409)§
and
LightCycler
2.0
Enterococcus Rectal swab
Xpert vanA
(surveillance)
(K092953)†
and
GeneXpert
System†
C. difficile
Unformed
Xpert C. difficile
(liquid or soft)
(K091109)†
stools
and
GeneXpert
System†
Prodesse
ProGastro Cd
(K090239)¶
BD GeneOhm
Cdiff Assay
(K081920)‡
Illumigene C.
difficile
(K091109)储

Real-time
PCR

Real-time
PCR

Target

Sensitivity (%)*

Staphylococcal protein MRSA % positive
A (spa), the gene for
agreement with
MecA-mediated
culture, 93.8;
oxacillin resistance
SA % positive
(mecA), and
agreement with
SCCmec inserted in
culture, 95.7
the SA chromosomal
attB site
SCC inserted into the
% positive
SA chromosomal
agreement,
attB site
80.9–90.6

MRSA % negative
agreement with
culture, 97.3;
SA % negative
agreement with
culture, 89.5
% negative
agreement,
92.3–96.3

SCCmec-orfXjunction
area of the
SCCmecadjacent to
the integration site
MREJ
SCC inserted into the
SA chromosomal
attB site

% positive
agreement,
80.9–90.6

% negative
agreement,
92.3–96.3

Real-time
PCR

Sequence
incorporating the
insertion site of the
SCCmec in the SA
orfX gene

% positive
agreement with
direct
chromogenic
culture, 95.2

% negative
agreement with
direct
chromogenic
culture, 96.4

Real-time
PCR

Gene sequences for
VanA-encoded
resistance to
vancomycinteicoplanin
C. difficile tcdB

98–99

81–90

93.50

94.0

Multiplex
C. difficile tcdB found
real-time
only in toxigenic
PCR
strains
Real-time
C. difficile tcdB
PCR

91.7

94.7

93.8

95.5

LAMP
C. difficile tcdA of the
technology PaLoc

95.2

95.3

Real-time
PCR

Real-time
PCR

92.00

Specificity (%)*

94.6

LAMP, loop-mediated amplification; PaLoc, pathogenicity locus; SCC, staphylococcal cassette chromosome.
*Sensitivity, specificity, and percentage positive or negative agreement with culture data are sourced from FDA submission material or product inserts.
†
Obtained from Cepheid, Sunnyvale, CA.
‡
Obtained from BD Diagnostics-Infectious Diseases, LaJolla, CA.
§
Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
¶
Obtained from Gen-Probe Prodesse, Inc., Waukesha, WI.
储
Obtained from Meridian Bioscience, Inc., Cincinnati, OH.

bacterial DNA, transcription-mediated amplification amplifies specific regions of the 23S rRNA/16S rRNA. The
APTIMA COMBO 2 assay does not have an internal control; however, it uses target capture technology, which
removes inhibitors. The assay is a dual kinetic assay, with
one signal scoring for CT and the second signal scoring
for NG. Assays that target bacterial rRNA rather than
plasmid DNA have a greater ability to detect lower con-

centrations of organisms because of the presence of up
to a 1000-fold greater amount of RNA than plasmid DNA
in the infected cell.
Cryptic plasmid– based detection assays could yield
false-negative results because CT strains without the
plasmid or with deletions in the plasmid have been described (the Swedish variant, with a 377-bp fragment
deletion). False-negative results have been reported for
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the Roche AMPLICOR and the Abbott RealTime CT/NG
assays that target the deleted region, whereas those
assays that target outside of this region or the chromosomal regions detect the mutant strain.21 The BD ProbeTec assay is able to detect the CT Swedish variant
because the cryptic plasmid target is outside the area of
deletion. The newer Abbott RealTime CT/NG assay, FDA
cleared in June 2010, includes an additional 140-bp
cryptic plasmid target outside of the 377-bp deletion
area. The Abbott RealTime CT/NG assay also contains a
small fragment of noninfectious linearized DNA plasmid
for use as an internal control throughout the sample preparation process.
A low prevalence of STDs in a specific population may
reduce the positive predictive value of the molecular result. However, the test can be repeated with a separate
aliquot of the same specimen or a second specimen and
a different test method and/or a different target to confirm
the positive result.20 The efficacy of this strategy is
debatable.22

HIV-1 Assay
Qualitative assays, such as the Procleix ULTRIO and
Discriminatory HIV-1/HCV/HBV assays (Gen-Probe Inc.)
and the COBAS AmpliScreen HIV-1 test (Roche Molecular Systems, Pleasanton), are available for donor screening applications. The transcription-mediated amplification– based APTIMA HIV-1 RNA qualitative assay (GenProbe Inc.) can be used for diagnosing acute and
primary infections and can detect infection before seroconversion and confirm infections in individuals when
antibody test results are positive.23,24 However, in this
segment, we will focus on the quantitative and genotyping assays that are the main HIV-1–related assays performed in the Molecular Diagnostics Laboratory.
HIV-1 viral load assays are important for monitoring
HIV-1–infected individuals, predicting the progression of
HIV disease, and monitoring antiretroviral treatment.25,26
HIV-1 is classified into three major groups (ie, M, N, and
O). Group M is the most prevalent and is sub-classified
into seven subtypes (ie, A–D and F–H) that are geographically distinct. Several commercial kits are available for
quantitative determination of HIV viral load to assess patient prognosis during antiretroviral therapy (Table 1).
Ascertaining the viral load is a prerequisite to initiating
drug therapy in adherence to FDA guidelines and serves
to evaluate the efficacy of antiretroviral therapy (http://
www.aidsinfo.nih.gov/guidelines, last accessed December 31, 2010). In 1996, the AMPLICOR HIV-1 MONITOR
test (Roche Molecular Systems) was the first FDA-approved quantitative HIV end point– based RT-PCR assay.
Quantification of HIV-1 RNA copy number is determined
by comparing optical density readings of the HIV-1 signal
with an external quantitation standard signal, which has a
known copy number input. However, a small dynamic
range of 400 to 750,000 copies/mL (or 50 to 100,000
copies/mL for the ultrasensitive method) limits the assay.
Recently, real-time RT-PCR HIV assays with options of
automation, closed-system platform characteristics,
broad dynamic range, and good specificity have become

commercially available.27 By using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test (Roche Molecular Systems), patient specimens are extracted on the COBAS
AmpliPrep instrument and amplification/detection occurs
on the COBAS TaqMan Analyzer. The assay targets the
conserved region in the gag gene, which is prone to a
high level of mutation and is only intended for the detection of group M subtypes of HIV-1. Calibration is not
required because specific calibration values and predefined assay control ranges are included with each kit
and because uracil-N-glycosylase reduces the risk of
carryover contamination. Initial underestimations regarding quantification of HIV-1 group M non-B subtypes,
when compared with the COBAS AMPLICOR HIV-1
MONITOR Version 1.5 and the Abbott RealTime HIV-1
assay, have been reported.28 –32 A second version of the
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test version
2.0 (Roche Molecular Systems) was recently approved.
This assay improves the underquantification and subtype
inclusivity issues present with the original assay. The
version 2.0 assay uses a two-target approach with the
combination of the new ltr primer-probe set with the original gag primer-probe set to detect the various group M
HIV-1 subtypes A–D and F–H and group O. The assay
has a quantitation range of 20 to 107 RNA copies/mL.33,34
With the Abbott RealTime HIV-1 kit (Abbott Molecular,
Inc., Abbott Park, IL), patient specimens are extracted on
the m2000sp instrument and detected on the m2000rt
instrument. The assay allows for flexibility in the sample
input volumes and detects both group M and group O
HIV-1 subtypes. In contrast to these real-time PCR-based
assays, the VERSANT HIV-1 RNA 3.0 Assay (Siemens
Health Care Diagnostics, Deerfield, IL) uses branched
DNA chemistry, which relies on signal amplification. The
assay has a lower risk of contamination because of the lack
of amplicon production, and the VERSANT HIV-1 RNA 3.0
Assay has been validated for samples containing group M
subtypes A–G (in 2002, subtype E was still believed to be a
true subtype); however, it has decreased sensitivity compared with target amplification assays.35,36
During treatment of HIV infections, mutant HIV-1
strains emerge that are resistant to one or more drugs.37
The identification of viral resistance genotypes allows
treatment strategies to be modified.38 Retrospective and
prospective intervention-based studies38 – 41 have provided evidence supporting the clinical utility of genotype
testing for resistance, and this is recommended by the
International AIDS Society–USA panel for selecting new
regimens after treatment failure and monitoring therapy
for pregnant women. Genotype testing should also be
considered before initiation of therapy for acute infections
and for treatment-naïve patients with established
infection.38
Two genotyping systems are commercially available:
TRUGENE HIV-1 Genotyping Kit (Siemens Diagnostics,
Tarrytown, NY) and ViroSeq HIV-1 Genotyping Systems
(Celera Diagnostics, Alameda, CA). The ViroSeq kit provides reagents for viral RNA isolation from plasma, and
both kits provide reagents for RT-PCR and sequencing.39,40,42 Typically, the entire protease and the 5= reverse transcription coding regions of the pol gene are
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Table 3.

Respiratory Tract and CNS Infection Assays
Organism

Specimen/sample type

Platform/assay (FDA no.)

Respiratory virus panel: influenza A/H1 and
A/H3; influenza B; adenovirus; RSV;
metapneumovirus (hMPV); parainfluenza
(hPIV) 1, 2, and 3; and rhinovirus

Nasopharyngeal swab

xTAG Respiratory Viral Panel (K063765)†

Respiratory virus panel: influenza A and B
and RSV

Nasopharyngeal swab, cultured
clinical specimens

Verigene Respiratory Virus Nucleic Acid Test
(K083088)‡ and Verigene Respiratory
Virus Nucleic Acid Test on the Verigene
SP system (K092566)‡
ProFlu⫹ (K073029, K081030, K092500)§ and
SmartCycler¶

Nasopharyngeal swab

Simplexa Flu A/B and RSV (K102170)储;
MagNA Pure LC Instrument and the
MagNA Pure Total Nucleic Acid Isolation
Kit** or a Qiagen QIAamp Viral RNA Mini
Kit†† and 3M Integrated Cycler‡‡
Simplexa Influenza A H1N1 (2009)
(K100148)储; MagNA Pure LC Instrument
and the MagNA Pure Total Nucleic Acid
Isolation Kit** or a Qiagen QIAamp Viral
RNA Mini Kit†† and 3M Integrated Cycler‡‡
CDC Human Influenza Virus Real-Time RTPCR Detection and Characterization Panel
(K101564)§§ and Applied Biosystems 7500
Fast Dx Real-Time PCR Instrument¶¶
ProFAST⫹ (K101855)§ and SmartCycler¶

Respiratory virus panel: influenza A and B
and RSV

Nasopharyngeal swab

Respiratory virus: influenza A/H1N1-2009

Nasopharyngeal swabs, nasal
swabs, NPAs

Respiratory virus: influenza A/H1N1-2009

Nasopharyngeal swabs and
nasal swabs

Respiratory virus panel: seasonal influenza
A/H1, A/H3, and A/H1N1-2009

Nasopharyngeal swab

Respiratory virus: influenza A/H5 (Asian
lineage)

Nasopharyngeal and throat
swabs

JBAIDS Influenza A subtype A/H5 (Asian
lineage) (K100287)储储 and JBAIDS
Instrument

Respiratory virus: hPIV

Nasopharyngeal swab

ProParaFlu⫹ (K091053)§ and SmartCycler¶

Respiratory virus: hMPV

Nasopharyngeal swab

Pro hMPV⫹ (K082688)§ and SmartCycler¶

Respiratory virus: adenovirus

Nasopharyngeal swab

ProAdeno⫹ (K102952)§ and SmartCycler¶

Enterovirus

CSF

Xpert EV (K061062) and GeneXpert System¶

CSF

NucliSENS EasyQ Enterovirus (K063261)***
and NucliSENS EasyQ System
AMPLIFIED MTD (Mycobacterium
Tuberculosis Direct) Test
(P940034/S008)†††
(table continues)

MTB

Sputum and bronchial
specimens

*Sensitivity, specificity, and percentage positive or negative agreement with culture data are sourced from FDA submission material or product inserts.
†
Obtained from Luminex Corporation, Austin, TX.
‡
Obtained from Nanosphere, Inc., Northbrook, IL.
§
Obtained from Gen-Probe Prodesse, Inc., Waukesha, WI.
¶
Obtained from Cepheid, Sunnyvale, CA.
储
Obtained from Focus Diagnostics, Inc., Cypress, CA.
**Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
††
Obtained from Qiagen, Gaithersburg, MD.
‡‡
3M, St Paul, MN.
§§
Obtained from the CDC, Atlanta, GA.
¶¶
Obtained from Life Technologies Inc., Carlsbad, CA.
储储
Obtained from the Department of Defense.
***Obtained from bioMérieux Inc., Durham, NC.
†††
Obtained from Gen-Probe, Inc., San Diego, CA.
hMPV, human metapneumovirus; hPIV, human parainfluenza virus; NASBA, nucleic acid sequence-based amplification; NPA, nasopharyngeal aspirate.
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Table 3.

Continued
Method

RT-PCR, allele-specific primer
extension, tag sorting

Target
Matrix gene of influenza A, Hemagglutinin
gene of influenza A/H1 and A/H3
Influenza B, adenovirus, RSV A/B
metapneumovirus
Parainfluenza 1, 2, and 3; and rhinovirus

Sensitivity (%)*

Specificity (%)*

Influenza A, 96.4

Influenza A, 95.9

Influenza A/H1, 100

Influenza A/H1, 100

Influenza A/H3, 91.7
Influenza B, 91.5
RSV A, 100
RSV B, 100
Adenovirus, 78.3
hMPV, 96
hPIV 1, 100
hPIV 2, 100
hPIV 3, 84.2
Rhinovirus, 100
Influenza A, 99.2
Influenza B, 96.8
RSV, 89.8

Influenza A/H3, 98.7
Influenza B, 96.7
RSV A, 98.4
RSV B, 97.4
Adenovirus, 100
hMPV, 98.8
hPIV 1, 99.8
hPIV 2, 99.8
hPIV 3, 99.6
Rhinovirus, 91.3
Influenza A, 90.1
Influenza B, 98.5
RSV, 91.5

Multiplex RT-PCR multiplex gold
nanoparticle hybridization
technology Verigene System‡

Influenza A matrix gene
Influenza B NS and matrix genes
L and F genes of RSV

Multiplex real-time RT-PCR
TaqMan chemistry

Influenza A matrix gene
Influenza B non-structural NS1 and NS2
genes
RSV polymerase gene
Target RNA of highly conserved region of
matrix protein genes of influenza A and
B and RSV

Influenza A, 100
Influenza B, 97.8

Influenza A, 92.6
Influenza B, 98.6

RSV, 89.5
Influenza A, 100
Influenza B, 100
RSV, 98

RSV, 94.9
Influenza A, 99.3
Influenza B, 99.8
RSV, 96.9

Real-time PCR

Influenza A matrix gene and unique
region in Hemagglutinin gene of 2009
H1N1 influenza virus

% positive agreement
for swabs, 100;
NPA, 100

% negative agreement
for swabs, 92.5;
NPA, 96.1

Real-time PCR

Influenza A matrix gene and
Nucleoprotein gene specific for 2009
H1N1 and Hemagglutinin gene specific
for 2009 H1N1
Target RNA of conserved region of
Hemagglutinin gene

Real-time RT-PCR

Real-time RT-PCR

Real-time RT-PCR

Multiplex real-time RT-PCR
TaqMan chemistry
Real-time RT-PCR TaqMan
chemistry
Multiplex real-time PCR TaqMan
chemistry
Real-time PCR
NASBA
Transcription- mediated
amplification, hybridization
protection assay

Two target RNA sequences 5= and 3= of
the Hemagglutinin precursor cleavage
site within the conserved regions of the
Hemagglutinin gene of influenza A/H5
(Asian lineage) virus
Conserved regions of HemagglutininNeuraminidase gene of hPIV 1, 2, and 3
hMPV: Nucleocapsid gene
Adenovirus serotypes 1–51, Hexon gene
Consensus region of enterovirus, 5= UTR
between nucleotides 452 and 596
Enterovirus RNA
Mycobacterial 16S rRNA

96

96

% positive agreement
for A/H1, 100; A/H3,
100; A/H1N1-2009,
95.4
96.9–100

% negative agreement
for A/H1, 99.0; A/
H3, 99.0; A/H1N12009, 100
95.3–97.1

hPIV-1, 88.9
hPIV-2, 96.3
hPIV-3, 97.3
% positive agreement,
94.1
97.5

hPIV-1, 99.9
hPIV-2, 99.8
hPIV-3, 99.2
% negative
agreement, 99.3
95.6

96.3–100

97.0–97.2

70.9–100

99.3–100

96.9

100
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amplified to generate a large amplicon that is then used
as a sequencing template for multiple primers that generate a consensus sequence. Software is available for
comparing the consensus with a known reference, to
determine any mutations present, based on which treatment options are made available. These are kept current
by a panel of HIV experts and recommendations of the
International AIDS Society–USA panel.37,43,44 Reportedly, genotyping assays may have limitations of sensitivity in detecting a minority variant species in a patient.45 In
addition, potential mutations may be missed at positions
not previously characterized as resistance mutants.

HSV Data
Herpes simplex virus (HSV) is one of the most common
STDs in the United States. Genital herpes is a chronic
life-long infection caused primarily by HSV-2, although
the role of HSV-1 is increasing.46,47 Most patients infected with genital herpes are asymptomatic, and the
clinical presentation is diverse. Because of the availability
of effective antiviral therapy, there is an increased demand for rapid accurate laboratory diagnosis of HSV.
HSV genotyping may aid in tracing of contacts and in
case evaluation.48,49 The MultiCode-RTx HSV-1&2 Kit
(EraGen Biosciences, Madison, WI) is a PCR-based qualitative IVD HSV typing assay, using vaginal swab specimens from symptomatic female patients. The assay is not
approved for cerebrospinal fluid (CSF) or any other genital or oral lesion specimens. The assay uses fluorophorelabeled HSV-1 and HSV-2 primers that target the glycoprotein B gene. The extraction methods cleared for the test
include the MagNA Pure LC Instrument and the MagNA
Pure LC Total Nucleic Acid Isolation Kit (Roche Molecular
Diagnostics). The PCR amplification is performed using the
LightCycler 1.2 instrument (Roche Molecular Diagnostics),
after which the HSV genotypes are discriminated by melt
curve analysis. Evaluation of the appropriate specimen/lesion and specimen collection procedures is essential because lesion type and location may affect the sample quality and the assay performance.

HAI Data
Different HAI assays have specific intended uses, such
as surveillance, presurgical, and diagnostic testing; and
the product insert should be reviewed carefully before
implementation.

MRSA Data
Methicillin resistance is associated with increased mortality in patients with staphylococcal bacteremia.50 Approximately half of all Staphylococcus aureus pneumonias
in the United States are due to methicillin-resistant S.
aureus (MRSA).51 MRSA ventilator-associated pneumonias also appear to be associated with a higher mortality
rate compared with methicillin-sensitive S. aureus ventilator-associated pneumonias.52 Patients colonized with
MRSA (nasal carriers) are also at increased risk of devel-

oping MRSA disease and can spread the infection as
well.
For direct MRSA detection from patient samples, the
Xpert MRSA, Xpert SA Nasal Complete assays for the
GeneXpert System (Cepheid, Sunnyvale, CA), the BD
GeneOhm MRSA ACP (BD Diagnostics, La Jolla, CA),
and the LightCycler MRSA Advanced test (Roche Molecular Systems) can be used. The GeneXpert System is a
fully integrated and automated nucleic acid preparation,
amplification, and real-time detection system. The Xpert
SA Nasal Complete (Cepheid) assay can be used for
surveillance of both S. aureus and MRSA carrier status,
which can aid in reducing the risk of HAIs. In a recent
multicenter clinical evaluation, no statistically significant
performance differences were observed between the
Xpert MRSA and MRSA ACP assays compared with culture.53,54 The recently approved LightCycler MRSA Advanced test was similarly evaluated compared with the
BD GeneOhmMRSA ACP and had a similar sensitivity
(92.2% and 93.2%, respectively) but a significantly better
specificity (98.9% and 94.2%, respectively).55 All of these
assays target the S. aureus orfX gene sequence incorporating the insertion site (attBssc) of the staphylococcal
cassette chromosome mec (SCCmec) for the detection of
MRSA. Targeting the mecA alone could result in false
positivity because a large percentage of coagulase-negative staphylococcus species would also test positive.
False-negative results can occur as the result of novel
SCCmec elements and variants resulting from recombination. Targeting the orfX region alone can give falsenegative results in those instances of mecA insertion into
other sites (although this is rare).56
Both the BD GeneOhm MRSA ACP and the BD GeneOhm StaphSR assays target the MREJ (types i to vii) of
the SCCmec insertion into the orfX gene and the S. aureus
species-specific nuc gene, which is distinct from the SCCmec cassette. Therefore, false-positive results are reduced. However, false-positive results may still occur
because of SCCmec variants with missing or nonfunctional mecA genes (empty cassette variants) and falsenegative results from MREJ variants other than types i
to vii.57
The LightCycler MRSA Advanced assay targets the
sequence incorporating the insertion site of the SCCmec
in the S. aureus orfX gene. Specifically, it targets types 2,
3, and 7 of the right extremity of the SCCmec-orfX junction. Thus, it may give false-negative results if the targeted right extremity types are not present. This assay
uses the uracil-N-glycosylase enzyme before amplification to eliminate any amplicon contamination. The Xpert
MRSA and Xpert SA Nasal Complete assays offer ease of
use, minimal hands-on time, and a closed-tube method of
testing. The assay can also be run either as a single
on-demand assay or in batch mode. In addition, the Xpert
SA Nasal Complete assay has high specificity because of
inclusion of three targets (spa, mecA, and SCCmec), reducing false-positive results due to empty cassette variants. In this assay, all three targets must be detected for
the assay to give a positive MRSA result. Therefore, coagulase-negative staphylococcus species, which may
contain the mecA gene but not the S. aureus–specific spa
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gene, will not render a positive MRSA result. Assays may
still test positive if there is mixed flora of both methicillinsensitive S. aureus and coagulase-negative staphylococcus species in the testing sample; however, the reported
incidence of such cocolonization is low.58
Cultured material can also be tested for the presence
of methicillin-susceptible or resistant S. aureus causing
sepsis (Table 4). Positive blood culture material may be
analyzed by the nonamplified peptide nucleic acid (PNA)
fluorescence in situ hybridization (FISH) method (AdvanDx, Woburn, MA). These pathogen-specific assays
are based on positive blood culture and Gram stain results for detecting S. aureus and MRSA as soon as the
instrument signal on continuously monitoring blood culture systems is positive.59 – 61 Small quantities of positive
blood culture material can also be analyzed using the
multiplex real-time PCR assays [BD GeneOhm StaphSR
(BD Molecular Diagnostics) and Xpert MRSA/SA BC
(Cepheid)]. The latter assay operates under a revised
Corrective Action Letter from Cepheid that instructs laboratories not to report an MRSA-negative result when an
MRSA-negative/SA-positive result is generated on the
Cepheid MRSA/SA Blood Culture Assay. Instead, MRSAindeterminate/SA-positive antimicrobial susceptibility
testing pending is the recommendation, with further antimicrobial susceptibility testing performed to determine
the MRSA status. The reporting of MRSA-positive/SApositive results generated on the Cepheid MRSA/SA
Blood Culture Assay is not affected.
Results can be achieved by real-time PCR, closed,
walk-away systems more rapidly than by more traditional
PCR assays. The commercial assays have excellent sensitivity and specificities when compared with culture. In
particular, genetic excisions within the SCCmec region of
MRSA strains may also yield positive PCR results in the
absence of a functional mecA gene and may cause PCRpositive but phenotypically methicillin-susceptible S. aureus results (empty cassette). This prevalence has differed by geographical region and appears to be more
common outside the United States.62,63 Decisions on
which assay to implement will depend on laboratory capabilities, the urgency for the result, and the impact on
patient care. It is recommended that the laboratory routinely perform clinical correlation of the assay results,
both positive and negative, to keep abreast of diverse
and evolving MRSA strains.

VRE Data
Screening for vancomycin-resistant enterococcus (VRE)
directly from perianal, perirectal, rectal, or stool specimens has been recommended by the CDC, Health Care
Infection Control Practices Advisory Committee (http://
www.cdc.gov/hicpac/mdro/mdro_0.html, last accessed
December 31, 2010) to limit the spread of antimicrobial
resistance within certain high-risk populations. For surveillance of VRE, the XpertvanA (Cepheid) assay can be
performed directly on rectal swab specimens from patients (Table 2). Gram-positive cocci in pairs and chains–
Enterococcus faecalis/other enterococci PNA FISH (AdvanDx) is also available to identify VRE from positive

blood culture results. Testing for VRE helps identify patients colonized with resistant enterococci in approximately 1 to 2 hours. Positive test results indicate the
presence of either the vanA or vanB gene, or vanA alone,
which confers vancomycin resistance in E. faecalis, Enterococcus faecium, and other bacteria that may colonize
the human intestine. In general, although a positive result
does not imply disease caused by VRE, the presence of
vanA or vanB genes correlates with colonization and clinical correlation is required to determine active VRE disease. PCR testing should decrease the spread of VRE by
rapid identification and isolation of colonized patients;
however, conventional bacterial cultures may still be required to isolate VRE from clinical specimens (eg, blood)
for the diagnosis of VRE infection. This approach allows
antimicrobial susceptibility testing for selection of appropriate antimicrobial treatment and strain typing of isolates
in outbreak situations.

Clostridium difficile Infection
C. difficile infection is an important cause of diarrhea in
patients who are hospitalized, in long-term care facilities
and receiving antibiotics, and in community settings.64
Four assays are available for the detection of toxigenic
strains of C. difficile (Table 2). The Illumigene C. difficile
assay (Meridian Bioscience Inc., Cincinnati, OH) uses
loop-mediated isothermal amplification technology to detect the pathogenicity toxin A gene (tcdA) in the pathogenicity locus of toxigenic C. difficile. The C. difficile pathogenicity locus is a gene segment present in several
known toxigenic C. difficile strains. It codes for both tcdA
and the toxin B gene (tcdB). The test includes a manual
extraction step but does not require costly capital equipment, and results are available in approximately 1 hour.
The Xpert C. difficile (Cepheid), BD GeneOhm Cdiff (BD
Diagnostics), and proGastro Cd (Gen-Probe Prodesse,
Inc., Waukesha, WI) assays are based on real-time PCR
and target tcdB of C. difficile. A positive test result does
not necessarily indicate the presence of viable C. difficile
organisms, but it does indicate the presence of tcdB.
Specimen extraction and amplification for the Xpert C.
difficile test is self-contained and automated, and the results are available in approximately 45 minutes. The BD
GeneOhm Cdiff assay results are available in ⬍2 hours.
Mutations or polymorphisms in primer- or probe-binding
regions may affect detection of C. difficile tcdA or tcdB
variants, resulting in false-negative results; however, variant toxigenic C. difficile without tcdB or with a nonfunctional toxin B protein is rare. An assay may be positive for
tcdB without TcdB toxin production (noncytotoxic, IX subtype), as reported in community-associated cases in
Canada.65 Because of the enhanced sensitivity of these
amplification methods, testing for C. difficile should be
limited to patients with clinical symptoms of C. difficile
infection. Testing should be limited to diarrheal or loose
stools (ie, those that take the shape of the container), and
the assays should also not be used for test of cure. Assay
performance is unknown for asymptomatic patients.66
Tables 2 and 4 list details of assays for HAIs.
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Table 4.

Other Organisms and Culture Confirmations

Organism
HCV quantitative

HCV qualitative
HBV quantitative

GBS

CA, GV, and TV

Group A
Streptococcus
Bacterial identification
from culture
Organisms causing
sepsis: GPCC

Organisms causing
sepsis: GPCPC
Organisms causing
sepsis: GPCPC
Organisms causing
sepsis: smears from
GNR
Organisms causing
sepsis: yeast

Specimen/sample type
EDTA plasma or serum

COBAS AmpliPrep/COBAS TaqMan HCV Test (P060030)†

Plasma or serum extracted from blood
collected using EDTA or ACD
Plasma or serum
EDTA plasma or serum
EDTA plasma or serum
EDTA plasma or serum

VERSANT HCV RNA 3.0 Assay (P020022)‡
APTIMA HCV RNA Qualitative Assay (P020011)§
AMPLICOR HCV test, version 2.0 (P000010)†
COBAS AMPLICOR HCV test, version 2.0 (P000012)†
COBAS TaqMan HBV Test (P050028)†

EDTA plasma or serum

RealTime HBV Assay (P080026)¶

Vaginal and rectal swabs incubated in
Lim broth overnight
Vaginorectal swab

BD MAX GBS assay and BD MAX System (K090191)储

Vaginorectal swab

Xpert GBS (K060540)**

Directly from vaginal and rectal swabs
or from LIM broth culture

Smart GBS test (K062948)**

Vaginal and rectal swabs incubated in
Lim broth overnight
Vaginal and anorectal swabs in Lim
broth culture
Vaginal sample

GBS PNA FISH (K082612)††

IDI-Strep B (K022504)储

AccuProbe Group B Streptococcus Culture Identification
Kit (K974572)§
BD Affirm VPIII Microbial Identification Tests (K931374,
K923133, K931151)储

Throat swab

GASDirect Test (K924715)§

Cultures
GPCC-positive cultures

AccuProbe Neisseria gonorrhoeae (K895583)§
AccuProbe Listeria monocytogenes (K901397)§
BD GeneOhm StaphSR (K071026)储

GPCC-positive cultures

Xpert MRSA/SA BC (K082140)**

GPCC-positive cultures
GPCC-positive cultures
GPCPC-positive cultures

S. aureus PNA FISH (K060099)††
S. aureus/CNS PNA FISH (K092166)††
AccuProbe S. aureus (K902213)§
AccuProbe Streptococcus pneumoniae (K902908)§

GPCPC-positive cultures

E. faecalis/OE PNA FISH (K083074)††

GNR-positive cultures

EC, PA
PNA FISH (K081309, K092236)††
EC, KP, PA PNA FISH (K101558)††

GNR-positive cultures
Smears made directly from yeastpositive blood cultures
Yeast-positive blood cultures

Mycobacterial
identification from
cultures

Platform/assay (FDA no.)

Growth from appropriate solid media
or broth

Candida albicans PNA FISH (K062461)††
Yeast Traffic Light PNA FISH (K080719)††
C. albicans/C. glabrata PNA FISH (K092784)††
AccuProbe Blastomyces dermatitidis (K903201)§
AccuProbe Coccidiodes immitis (K904047)§
AccuProbe Histoplasma capsulatum (K896859)§
AccuProbe M. avium (K896494)§
AccuProbe M. avium complex (K897078)§
AccuProbe Mycobacterium gordonae (K896492)§
AccuProbe Mycobacterium intracellulare (K897077)§
AccuProbe Mycobacterium kansasii (K904463)§
AccuProbe MTB complex (K896493)§
(table continues)
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Table 4.

Continued
Linear range (%)*
Method

Real-time RT-PCR
bDNA
Transcription-mediated amplification
RT-PCR
RT-PCR
Real-time PCR
Real-time PCR
Real-time PCR

Target

Sensitivity

Transcript of a 244-base sequence in the highly
conserved 5= untranslated region of HCV;
genotypes 1–6
5=UTR and core regions of the HCV genome
5=UTR of the HCV genome
5=UTR of the HCV genome
5=UTR of the HCV genome
Core-precore region of the HBV genome;
primer pairs to genotypes A–G of HBV and
the precore mutation
Surface (S) gene of the HBV genome; primer
pairs to genotypes A–G of HBV
124-bp region of the cfb gene

Specificity

43–69,000,000 IU/mL
3200–40,000,000 IU/mL
91.8–100
97.8–98.5
92–94
96–97
92–94
96–97
20–170,000,000 IU/mL
10–1,000,000,000 IU/mL
95

96.7

Real-time PCR SmartCycler
system**
GeneXpert System (real-time
PCR)**
Real-time PCR SmartCycler
system**

GBS cfb gene

94

95.9

3= region adjacent to the cfb gene

91.1

96.0

PNA-FISH

16S rRNA of Streptococcus agalactiae

Culture confirmation; hybridization
protection assay
Single-stranded DNA probes,
hybridize with complementary
rRNA target sequences to
form hybrids
Hybridization protection assay

DNA probe that detects rRNA sequences
unique to S. agalactiae
rRNA

Hybridization protection assay

rRNA
100
AccuProbe Listeria monocytogenes (K901397)§
100
SCCmec and mecA gene; nucA gene
MRSA % positive
agreement, 100

Real-time PCR

DNA 3= region adjacent to the cfb gene

rRNA

GeneXpert System (real-time
PCR)**

Spa and mecA genes and SCCmec inserted into
S. aureus chromosomal attB insertion site

FISH assay
Hybridization protection assay
Hybridization protection assay

Species-specific 16S rRNA of S. aureus‡‡
rRNA
rRNA

PNA; FISH assay
PNA; FISH assay

Species-specific 16S rRNA in E. faecalis and
other enterococci§§
Species-specific rRNA of EC and PA

PNA; FISH assay

Species-specific rRNA of EC, KP, and PA

PNA FISH species-specific
probes

16S rRNA of C. albicans

Hybridization protection assay

rRNA

Hybridization protection assay

rRNA

Direct from swabs,
81.6
From Lim broth, 98.7
89.2–100

Direct from swabs,
96.4
From Lim broth, 90.4
86.8–100

97.5
CA, 80.6
GV, 83.8
TV, 92.8

99.8
CA, 98.2
GV, 99.1
TV, 99.9

91.7

SA % positive
agreement, 98.8–
100
MRSA, 98.3
SA, 100
100
100
100
% positive agreement
with culture, 100
EC, 100
PA, 97.5
EC, 100
KP, 98.7
PA, 96.9
100
98.1
98.8
100
99.3
99.9
98.8
100
98.0
99.2

99.3
100
99.7
MRSA % negative
agreement, 98.2–
100
SA % negative
agreement, 96.5
MRSA, 99.4
SA, 98.6
100‡‡
100
100
% negative agreement
with culture, 100
100¶¶
100
EC, 97.5
KP, 97.5
PA, 97.5
100
99.7
100
100
100
100
99.7
100
96.8
99.9
(table continues)
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Table 4.

Continued

Organism
Mycoplasma species

Specimen/sample type
Tissue culture

Platform/assay (FDA no.)
Mycoplasma Tissue Culture NI (MTC-NI)
Rapid Detection System (K860574)§
(table continues)

*Sensitivity, specificity, linearity range, and percentage positive or negative agreement with culture data are sourced from FDA submission material or product inserts.
†
Obtained from Roche Molecular Diagnostics, Pleasanton, CA.
‡
Obtained from Siemens Healthcare Diagnostics, Deerfield, IL.
§
Obtained from Gen-Probe, Inc., San Diego, CA.
¶
Obtained from Abbott Molecular, Inc., Des Plaines, IL.
储
Obtained from BD Diagnostics, Sparks, MD.
**Obtained from Cepheid, Sunnyvale, CA.
††
Obtained from AdvanDx, Inc., Woburn, MA.
‡‡
False-positive results with Staphylococcus schleiferi may occur because of a single-base mismatch.
§§
Enterococcus moraviensis is identified as E. faecalis because of sequence identity.
¶¶
False-positive results may occur with Shigella species (serogroups A, B, C, or D), Escherichia albertii, and Escherichia fergusonii because of sequence similarity.
ACD, anticoagulant citrate dextrose; bDNA, branched DNA; CA, Candida species; EC, Escherichia coli; GNR, Gram-negative rod; GPCC, Gram-positive
cocci in clusters; GPCPC, Gram-positive cocci in pairs and chains; GV, Gardnerella vaginalis; KP, Klebsiella pneumonia; PA, Pseudomonas aeruginosa; TV,
Trichomonas vaginalis.

Respiratory Tract and CNS Infections
Detection of MTB Complex from Clinical Specimens
Data for the United States describe 11,181 cases of
tuberculosis infections in 2010. Approximately one third
of the 40 million people living with HIV/AIDS worldwide
are coinfected with tuberculosis. People with HIV are up
to 50 times more likely to develop tuberculosis in a given
year than HIV-negative individuals (World Health Organization, http://www.who.int/tb/challenges/hiv/en/index.html, last
accessed December 31, 2010). Several strains of Mycobacterium tuberculosis (MTB) are resistant to multiple antibiotics, and detection of these strains is critical for patient treatment and public health concerns.
The AMPLIFIED MTD (Mycobacterium Tuberculosis
Direct) Test (Gen-Probe Inc.) (Table 3) is the only FDAapproved test available for the qualitative detection of
MTB. The assay detects MTB complex rRNA directly from
smear-positive and smear-negative sputum, bronchial
specimens, and tracheal aspirates, with results available
in ⬍4 hours. The sensitivity and specificity of the MTD
assay are 72% and 99.3%, respectively, for smear-negative patients and 96.9% and 100%, respectively, for
smear-positive patients (package insert, IN0014 revision
L, dated August 2001). Other specimen types (eg, CSF,
blood, and lymph node tissue) are not FDA approved for
use with this assay. Culture of the specimen is still required given the imperfect sensitivity of the MTD assay
for smear-negative specimens and for susceptibility testing. Non-specific inhibition was reported in 3% to 7% of
sputum specimens. Pollock et al67 have shown that dilution of the processed sputum sediment by 1:10 using an
MTD reaction buffer overcomes non-specific inhibition
and improves sensitivity of the MTD assay. However, this
dilution technique is not part of the FDA-approved assay.
A positive MTD result in a smear-positive patient helps to
initiate antimycobacterial drug therapy much earlier than
awaiting culture results. The decision to remove patients
from isolation should not be based solely on a negative
MTD test result because of imperfect sensitivity, especially in smear-negative patients. The limit of detection of

the AMPLIFIED MTD assay is one colony-forming unit per
test. Because of the global importance of tuberculosis,
nucleic acid tests are recommended by the CDC and the
American Thoracic Society to improve detection and
treatment of this infection (http://www.cdcnpin.org/
scripts/tb/cdc.asp, last accessed December 31, 2010).

Respiratory Tract Viral Infections
Acute respiratory tract infections are the most common
infections in humans, and respiratory tract viruses cause
80% of these infections. Respiratory tract virus infections
range from mild self-limiting upper respiratory tract infections to severe lower respiratory tract infections. Influenza
causes 200,000 hospitalizations and 36,000 deaths in the
United States annually, and respiratory syncytial virus
(RSV) is the most common cause of severe lower respiratory tract disease in infants and young children worldwide (World Health Organization, http://www.who.int/
vaccine_research/diseases/ari/en, last accessed December 31, 2010). Influenza A and B and RSV account for the
most serious respiratory tract diseases, with antiviral therapy available for treatment.
The commercially available IVDs for respiratory viral
agents include single or multiple pathogen (multiplex
panel) detection and devices for the identification or typing of these causative agents (Table 3). Because most of
the respiratory viral agents cause similar symptoms, the
multiplex assays provide the added value of enabling the
simultaneous detection of multiple agents with a single
test. Several multiplex panels are available, and their
applications will be laboratory and patient population
dependent.
Several closed-tube real-time PCR systems are available for the detection of respiratory tract viruses. These
include the proFlu⫹ (Gen-Probe Prodesse, Inc.) test,
which simultaneously detects influenza A and B and RSV,
with a platform designed for a high-throughput laboratory. The Verigene System (Nanosphere, Inc., Northbrook, IL) and the Simplexa Flu A/B and RSV (Focus
Diagnostics, Inc., Cypress, CA) detect influenza A and B
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Table 4.

Continued
Linear range (%)*
Method

DNA probe

Target

Sensitivity

rRNA of Mycoplasma and Acholeplasma
species

and RSV. The ProParaFlu⫹ (Gen-Probe Prodesse, Inc.)
detects parainfluenza 1, 2, and 3; and the Pro hMPV⫹
(Gen-Probe Prodesse, Inc.) detects human metapneumovirus (Table 3). The pro hMPV⫹ assay shows 94.1%
sensitivity and 99.3% specificity against a composite reference method of RT-PCR targeting the nucleocapsid
and fusion genes of hMPV. The ProAdeno⫹ (Gen-Probe
Prodesse, Inc.) assay is approved for qualitative detection of human adenovirus serotypes 1 to 51 in nasopharyngeal specimens. Compared with shell vial culture, the
ProAdeno⫹ assay is 98% sensitive and 96% specific.
The ProParaflu⫹ assay is approved for qualitative detection of parainfluenza 1, 2, and 3 from nasopharyngeal
swab specimens. The ability of the ProParaflu⫹ assay to
detect parainfluenza virus 1, 2, and 3 ranges from a
sensitivity of 89% to 97% and from a specificity of 99% to
100% when compared with culture. The ProFAST⫹ assay
is designed to detect and differentiate influenza A/H1,
influenza A/H3, and the 2009 H1N1 influenza from nasopharyngeal specimens. Additional IVDs for influenza A
and H1N1 influenza are the Simplexa Influenza A H1N1
(2009) (Focus Diagnostics, Inc.) and the CDC influenza
assay. However, the CDC assay is not commercially
available. The FDA also cleared the Department of Defense biological warfare agent detection device, the
JBAIDS diagnostic system for Influenza A/H5 (avian influenza) diagnosis. The JBAIDS assay is not available for
general commercial use.
A moderately multiplexed assay, such as the xTAG
Respiratory Viral Panel (Luminex Corp, Austin, TX), detects a panel of 12 viruses and subtypes influenza seasonal H1 and H3 viruses. By using decision tree modeling, Mahony et al68 demonstrated that the least costly
strategy to diagnose respiratory tract virus infection was
the xTAG RVP (Luminex Corporation, Austin, TX) test
alone when the prevalence of infection was ⱖ11% and
DFA (Direct Fluorescent Antibody) alone when the prevalence was ⬍11%. The xTAG assay is relatively complex,
and the assay’s open-tube format has the potential for
contamination. The assay is approved for nasopharyngeal swab specimens. The assay cannot adequately detect adenovirus species C or serotypes 7a and 41, and

Not applicable

Specificity
Not applicable

rhinovirus is not differentiated from enterovirus (EV). A
nonsubtypable influenza A result must also be carefully
evaluated because this may be the first indication of an
epidemic caused by a new influenza strain. In addition to
the potential of detecting more viral coinfections, the multiplex assays, although not FDA cleared for this population, may prove useful in the evaluation of immunosuppressed patients and in older patients in whom viral titers
may typically be lower.69
CNS Viral Infections
Viral CNS infections usually manifest as meningitis and
encephalitis. Although several microorganisms are associated with CNS infections, the only MID IVD available is
for EV, the leading cause of seasonal meningitis. Nucleic
acid testing aids in rapid diagnosis of viral meningitis and
prevents unnecessary antibiotic use and potential repeat
spinal taps, especially in children.70,71 More recently,
rapid nucleic acid amplification tests, including real-time
RT-PCR, nucleic acid sequence-based amplification,
and fully automated systems capable of extraction, amplification, and detection, have replaced conventional
RT-PCR methods.72–75 CSF is the diagnostic specimen
for detection of EV in patients with aseptic meningitis.
Pleocytosis and elevation of protein level in CSF are good
markers for CSF infection. The absence of pleocytosis in
CSF may be a good predictor of a negative EV RT-PCR
result in children ⬎2 months. However, elevation of the
CSF protein level is not a good predictor of RT-PCR
positivity for EV.76
Two qualitative IVDs are available for testing CSF
specimens for EV: Xpert EV (Cepheid) and NucliSENS
EasyQ Enterovirus (bioMérieux, l’Etoile, France). The
Xpert EV assay is performed on a GeneXpert System
(Cepheid). In a multicenter evaluation of 102 CSF specimens, the assay had a sensitivity of 97.1% (95% CI,
84.7% to 99.9%) and a specificity of 100% (95% CI,
94.6% to 100%) when compared with culture.74 Although
this initial study demonstrated that moderate amounts of
blood did not interfere with assay performance, a subsequent study77 indicated that the presence of red blood

600
Emmadi et al
JMD November 2011, Vol. 13, No. 6

cells could produce an invalid result in up to 8.2% of CSF
specimens. It also showed that xanthochromia and specimen clotting did not affect results. Specimens with any
invalid results could be diluted at 1:5 or repeat tested
after a freeze-thaw cycle to overcome inhibition, with a
minimal reduction in sensitivity (⬍3.6%). This is an easyto-use assay format that affords random access capability and minimal hands-on time, with results available in
⬍2.5 hours.
The NucliSENS EasyQ Enterovirus assay (bioMérieux),
a nucleic acid sequence-based amplification, involves
nucleic acid extraction, amplification, and real-time detection of an internal control and EV RNA by Molecular
Beacons that are labeled with two different dyes: 6-FAM
for EV and 6-ROX for the internal control. In a study of 449
prospectively collected CSF specimens tested by cell
culture and NucliSENS EasyQ Enterovirus, method
agreement was 86.4% (95% CI, 79.3% to 91.2%; FDAK063261 submission data). In a premarket evaluation
study, 73 this assay was more sensitive than culture
(97.9% versus 65.6%; P ⬍ 0.001) and inhibition was
noted in only 0.5% of CSF specimens. The GeneXpert
System and nucleic acid sequence-based amplification
assays were compared in a recent multicenter trial for
detection of EV from CSF and had a sensitivity of 100%
and 87.5%, respectively.75 Table 3 lists assays for respiratory tract and CNS infections.

Other Infections
HBV Data
HBV infection is a global public health problem, with 400
million worldwide long-term carriers and up to 25% mortality.78,79 HBV is classified with A–H genotypes, and
prevalence varies greatly by geography and population
subgroups. Because there are significant differences in
genotype-dependent hepatocellular carcinoma, it is essential to detect and quantitate all genotypes. Typically,
the conserved region in the precore/core or N-terminal
portion of the S gene is targeted for target amplification
assays; and multiple probes are used to detect all genotypes. There is no role for molecular testing in the diagnosis of acute HBV other than in the detection of asymptomatic patients during pretransfusion screening of blood
products.
There are two commercial FDA-approved assays for
HBV quantification (Table 4). The COBAS TaqMan HBV
Test for use with the manual High Pure System Viral
Nucleic Acid Kit (Roche Molecular Diagnostics) is approved for serum and plasma specimen types. Quantification of HBV viral DNA is performed using the quantitation standard that is incorporated in each sample. The
dynamic range of the test is 29 to 110,000,000 IU/mL,
with a limit of detection of 10 IU/mL. The RealTime HBV
assay on the m2000 system (Abbott Molecular) has recently been approved to quantify HBV viral load in
plasma and serum. This test has a detection capability
that ranges from 10 to 1 billion IU/mL and spans all known

HBV genotypes (A–H). The same quantitative test should
be used throughout a patient’s treatment course.

HCV Data
Hepatitis C virus (HCV) infection is the most common
cause of chronic viral hepatitis. Nearly 20% of the 4
million carriers develop liver cirrhosis. Viral RNA can be
detected in HCV-infected individuals as early as 1 to 4
weeks before the increase of liver enzymes, and it peaks
in the first 8 to 12 weeks after infection.80 HCV infections
are typically diagnosed by the detection of antibodies
directed against specific HCV antigens. However, HCV
serological tests demonstrate low specificity and may
require confirmation of positive results. Qualitative PCR
assays, such as the FDA-cleared Cobas AMPLICOR HCV
Test, version 2.0 (Roche Molecular Diagnostics), the APTIMA HCV RNA qualitative assay (Gen-Probe Inc.), or the
VERSANT HCV RNA Qualitative assay (Siemens Diagnostics), can be used to confirm serological findings.
Treatment for chronic HCV typically consists of a combination of pegylated interferon-␣ and ribavirin, and response to therapy is genotype dependent. Quantitative
viral load assays are used to establish viral load at baseline, monitor viral load during therapy, and determine
response to treatment. Both the rapid and complete early
virologic responses have been used to predict if a patient
will achieve a sustained virologic response. The early
virologic response is defined as a ⱖ2-log10 reduction in
HCV RNA levels during the first 12 weeks of therapy. The
rapid and complete early virologic responses are defined
as no virus detected at 4 and 12 weeks after initiation of
antiviral agent, respectively.81 A completely negative test
result for HCV RNA at week 12 (complete early virologic
response) is a better predictor of a sustained virologic
response than a 2-log10 reduction in HCV RNA.82 A sustained virologic response is achieved when ⬍5 IU/mL
HCV RNA is detected after 24-week treatment. After this,
the treatment is discontinued for genotypes 2 and 3 and
continued for an additional 24 weeks for genotypes 1 and
4. Currently, there are no FDA-approved HCV genotyping
tests. Therefore, the quantitative assays used to measure
HCV viral load need to be sensitive and need to generate
accurate results for all genotypes and subtypes. The
same quantitative test should be used throughout a patient’s treatment course. The American Association for
the Study of Liver Diseases has published guidelines for
the use of qualitative and quantitative molecular assays
for detection and quantification of HCV RNA in serum and
plasma.83
There are two commercial FDA-approved assays for
HCV quantitation. The COBAS AmpliPrep/COBAS TaqMan System (Roche Molecular Diagnostics) is an automated real-time RT-PCR that targets a highly conserved
sequence in the HCV 5= untranslated region.84,85 The
VERSANT HCV RNA 3.0 Assay (branched DNA) (Siemens Healthcare Diagnostics) is a branched DNA signal
amplification method targeting highly conserved sequences in both the 5=UTR and the core gene.86 The
former method has a dynamic range of detection from 25
to 3.9 ⫻ 108 IU of HCV RNA/mL of plasma or serum. The
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range of the latter assay is from 615 to 7.69 ⫻ 106 IU of
HCV RNA/mL of plasma or serum.

for susceptibility testing. Susceptibility testing is of particular concern for women who are allergic to penicillin.

Group B Streptococcus

Fungal or Bacterial Identification from Culture

Streptococcus agalactiae [group B Streptococcus (GBS)]
is a leading cause of sepsis, meningitis, and death
among newborn infants in the Western world. Between
10% and 40% of healthy adult women are colonized by
GBS in the genital and gastrointestinal tracts; although
not associated with disease in healthy women, GBS can
cause disease during pregnancy and delivery.87 The
CDC, in collaboration with the American College of Obstetrics and Gynecology and the American Academy of
Pediatrics, issued revised guidelines that included recommending universal prenatal screening of all pregnant
women between 35 and 37 weeks of gestation to determine their vaginal/rectal GBS colonization status. The
CDC recommends universal antepartum GBS screening
in all pregnant women, primarily with culture from vaginalrectal swabs, to identify candidates for intrapartum prophylaxis to decrease early-onset GBS-related complications in the newborn.87 Use of vaginal-rectal swabs
improves GBS isolation by 40%, compared with use of
vaginal specimens alone.88 Culture requires up to 36
hours of incubation and, therefore, rapid screening using
molecular test methods may alleviate unnecessary antibiotic treatment in patients with preterm labor. A rapid
and sensitive intrapartum real-time PCR assay offers the
advantage of ascertaining the colonization status before
delivery.
Six assays are commercially available for GBS testing
(Table 4), using either direct vaginal-rectal swabs or
these swabs incubated in Lim broth (culture confirmation): AccuProbe Group B Streptococcus culture confirmation test (Gen-Probe Inc.), IDI-Strep B (GeneOhm Sciences, San Diego), BD MAX GBS assay (BD
Diagnostics), Smart GBS (Cepheid), Xpert GBS (Cepheid), and the GBS PNA FISH (AdvanDx) assay. The BD
MAX System (BD Diagnostics) is an integrated system
that uses probes (Molecular Beacons), whereas the GeneXpert (Cepheid) system uses TaqMan probes. The
Xpert GBS assay is the only FDA-cleared assay for use
on both intrapartum and antepartum specimens. FDAcleared molecular methods allow for increased sensitivity
and a rapid turnaround time. The GeneXpert system facilitates near-point-of-care analysis in an intrapartum scenario. The BD GeneOhm StrepB and the Smart GBS PCR
assays are not yet automated and require varying degrees of hands-on specimen manipulation and sample
preparation. In a high-volume laboratory setting, this may
not be practical. The BD MAX system allows automation
of a PCR assay that is run in a batch mode in the laboratory for antepartum testing. Although PCR tests have
initially been adopted selectively in facilities with sufficient demand and resources, a general recommendation
for their use by the CDC and other agencies would require the capacity for effective implementation in a wide
range of hospital settings. Some disadvantages of intrapartum PCR testing include delays in the administration
of antibiotics, pending test results, and lack of an isolate

Pathogen-specific rRNA PNA FISH probes can be selected based on a Gram stain result and are available for
bacteria and yeast. These probes have a high impact on
antimicrobial stewardship and HAI.59 – 61,89 –92 Candida
species are a leading cause of both community- and
hospital-associated fungemia. The identification of Candida species in blood cultures is routinely based on presumptive identification by Gram stain as yeast, followed
by final identification after subculture and biochemical
analysis. There are several PNA FISH assays available
from AdvanDx. The Yeast Traffic Light PNA FISH identifies Candida albicans/Candida parapsilosis, Candida tropicalis, and Candida glabrata/Candida krusei and aids in
appropriate drug therapy because of decreased susceptibility (C. glabrata) and inherent resistance (C. krusei) to
fluconazole. Because these MID IVDs do not provide
antimicrobial susceptibility profiles, culture should also
be performed.
AccuProbe kits (Gen-Probe Inc.) performed on culture
specimens can identify several fungi (Coccidioides immitis, Histoplasma capsulatum, and Blastomyces dermatitidis)
that require special handling in biological safety cabinets, thereby decreasing reporting times considerably.
Probes for bacteria include the following: GBS, Streptococcus pneumoniae, S. aureus, Listeria monocytogenes,
and NG. Mycobacterium kits are also available, including
probes to identify MTB complex, Mycobacterium avium
complex, and species-specific M. avium, Mycobacterium
intracellulare, Mycobacterium gordonae, and Mycobacterium kansasii. In contrast to molecular methods, traditional
biochemical methods to speciate Mycobacterium may
take as long as 2 months, whereas these probes can
complete identification in ⬍1 hour. Table 4 lists culture
confirmation and other assays.

Summary and Conclusions
This review is intended to provide the current state-ofthe-art information on FDA- cleared/approved molecular
assays to diagnose infectious diseases. The technology
has evolved rapidly over the past 25 years from a chemiluminescent probe performed on the routine bacteriology
bench top to sophisticated and automated platforms
where a patient specimen is extracted and molecular
targets are detected within short turnaround times. Although the application of MID tests in the diagnosis and
management of infectious diseases has greatly improved
health care, it is limited to institutions with certain capacities. The availability of well-characterized FDA-cleared or
FDA-approved MID tests reduces the burden on laboratories in developing or validating laboratory-developed
tests, facilitates implementation of molecular testing in
more laboratories, and allows for the standardization and
comparability of tests, thus greatly improving health care
outcomes. Because of the impact on patient care and the
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evolving technology, we can expect major changes in
molecular testing in the next few years.

Acknowledgment
We thank Dr. Haja Sittana El Mubarak (Office of in Vitro
Diagnostic Device Evaluation and Safety, Silver Spring, MD)
for her unstinting help, extensive feedback, and generous
donation of time in the preparation of the manuscript.

References
1. Edelstein PH: Evaluation of the Gen-Probe DNA probe for the detection of legionellae in culture. J Clin Microbiol 1986, 23:481– 484
2. Whelen AC, Persing DH: The role of nucleic acid amplification and
detection in the clinical microbiology laboratory. Annu Rev Microbiol
1996, 50:349 –373
3. Renub Research: Global Molecular Diagnostic Market: Opportunities
and Future Forecast. Rosewell, GA: 8/2009, RE-1503
4. Espy MJ, Uhl JR, Sloan LM, Buckwalter SP, Jones MF, Vetter EA, Yao
JD, Wengenack NL, Rosenblatt JE, Cockerill FR 3rd, Smith TF: Realtime PCR in clinical microbiology: applications for routine laboratory
testing. Clin Microbiol Rev 2006, 19:165–256
5. Burd EM: Validation of laboratory-developed molecular assays for
infectious diseases. Clin Microbiol Rev 2010, 23:550 –576
6. Jennings L, Van Deerlin VM, Gulley ML: Recommended principles
and practices for validating clinical molecular pathology tests. Arch
Pathol Lab Med 2009, 133:743–755
7. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F,
Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Cogliano V;
WHO International Agency for Research on Cancer Monograph Working Group: A review of human carcinogens–Part B: biological agents.
Lancet Oncol 2009, 10:321–322
8. Stoler MH, Castle PE, Solomon D, Schiffman M: The expanded use of
HPV testing in gynecologic practice per ASCCP-guided management
requires the use of well-validated assays. Am J Clin Pathol 2007,
127:335–337
9. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G,
Arbyn M, Bosch FX, Cuzick J, Dillner J, Heideman DA, Snijders PJ:
Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J
Cancer 2009, 124:516 –520
10. Cox JT: History of the use of HPV testing in cervical screening and in
the management of abnormal cervical screening results. J Clin Virol
2009, 45(Suppl 1):S3–S12
11. Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand
MH, Dillner J, Meijer CJ: Overview of human papillomavirus-based
and other novel options for cervical cancer screening in developed
and developing countries. Vaccine 2008, 26(Suppl 10):K29 –K41
12. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J,
Ferenczy A, Ratnam S, Coutlee F, Franco EL: Human papillomavirus
DNA versus Papanicolaou screening tests for cervical cancer. N Engl
J Med 2007, 357:1579 –1588
13. Kitchener HC, Almonte M, Gilham C, Dowie R, Stoykova B, Sargent A,
Roberts C, Desai M, Peto J: ARTISTIC: a randomised trial of human
papillomavirus (HPV) testing in primary cervical screening. Health
Technol Assess 2009, 13:1–150, iii-iv
14. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S, Schiffman M: Human papillomavirus genotype specificity of hybrid capture
2. J Clin Microbiol 2008, 46:2595–2604
15. Muldrew KL, Beqaj SH, Han J, Lum SH, Clinard V, Schultenover SJ,
Tang YW: Evaluation of a Digene-recommended algorithm for human
papillomavirus low-positive results present in a “retest zone.” Am J
Clin Pathol 2007, 127:97–102
16. Szarewski A, Ambroisine L, Cadman L, Austin J, Ho L, Terry G, Liddle
S, Dina R, McCarthy J, Buckley H, Bergeron C, Soutter P, Lyons D,
Cuzick J: Comparison of predictors for high-grade cervical intraepithelial neoplasia in women with abnormal smears. Cancer Epidemiol
Biomarkers Prev 2008, 17:3033–3042

17. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah
KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human
papillomavirus types associated with cervical cancer. N Engl J Med
2003, 348:518 –527
18. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford
GM: Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J
Cancer 2007, 121:621– 632
19. Belinson JL, Wu R, Belinson SE, Qu X, Yang B, Du H, Wu R, Wang C,
Zhang L, Zhou Y, Liu Y, Pretorius RG: A population-based clinical trial
comparing endocervical high-risk HPV testing using hybrid capture 2
and Cervista from the SHENCCAST II Study. Am J Clin Pathol 2011,
135:790 –795
20. Johnson RE, Newhall WJ, Papp JR, Knapp JS, Black CM, Gift TL,
Steece R, Markowitz LE, Devine OJ, Walsh CM, Wang S, Gunter DC,
Irwin KL, DeLisle S, Berman SM: Screening tests to detect Chlamydia
trachomatis and Neisseria gonorrhoeae infections–2002. MMWR Recomm Rep 2002, 51(RR-15):1–38; quiz CE1-4
21. Reischl U, Straube E, Unemo M: The Swedish new variant of Chlamydia trachomatis (nvCT) remains undetected by many European
laboratories as revealed in the recent PCR/NAT ring trial organised by
INSTAND e.V., Germany. Euro Surveill 2009, pii: 1930214:
22. Schachter J, Chow JM, Howard H, Bolan G, Moncada J: Detection of
Chlamydia trachomatis by nucleic acid amplification testing: our evaluation suggests that CDC-recommended approaches for confirmatory testing are ill-advised. J Clin Microbiol 2006, 44:2512–2517
23. Ethridge SF, Hart C, Hanson DL, Parker MM, Sullivan TJ, Bennett B,
Stephens P, Hilliard J, Patel P: Performance of the Aptima HIV-1 RNA
qualitative assay with 16- and 32-member specimen pools. J Clin
Microbiol 2010, 48:3343–3345
24. Fiebig EW, Wright DJ, Rawal BD, Garrett PE, Schumacher RT, Peddada L, Heldebrant C, Smith R, Conrad A, Kleinman SH, Busch MP:
Dynamics of HIV viremia and antibody seroconversion in plasma
donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871–1879
25. Barre-Sinoussi F, Chermann JC, Rey F, Nugeyre MT, Chamaret S,
Gruest J, Dauguet C, Axler-Blin C, Vezinet-Brun F, Rouzioux C,
Rozenbaum W, Montagnier L: Isolation of a T-lymphotropic retrovirus
from a patient at risk for acquired immune deficiency syndrome
(AIDS). Science 1983, 220:868 – 871
26. Popovic M, Sarngadharan MG, Read E, Gallo RC: Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III)
from patients with AIDS and pre-AIDS. Science 1984, 224:497–500
27. Sloma CR, Germer JJ, Gerads TM, Mandrekar JN, Mitchell PS, Yao
JD: Comparison of the Abbott realtime human immunodeficiency
virus type 1 (HIV-1) assay to the Cobas AmpliPrep/Cobas TaqMan
HIV-1 test: workflow, reliability, and direct costs. J Clin Microbiol
2009, 47:889 – 895
28. Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, BrunVezinet F, Descamps D: Human immunodeficiency virus type 1 (HIV-1)
plasma load discrepancies between the Roche COBAS AMPLICOR
HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS
TaqMan HIV-1 assays. J Clin Microbiol 2007, 45:3436 –3438
29. Gueudin M, Plantier JC, Lemee V, Schmitt MP, Chartier L, Bourlet T,
Ruffault A, Damond F, Vray M, Simon F: Evaluation of the Roche Cobas
TaqMan and Abbott RealTime extraction-quantification systems for
HIV-1 subtypes. J Acquir Immune Defic Syndr 2007, 44:500 –505
30. Wirden M, Tubiana R, Marguet F, Leroy I, Simon A, Bonmarchand M,
Ait-Arkoub Z, Murphy R, Marcelin AG, Katlama C, Calvez V: Impact of
discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group
M non-B subtypes. J Clin Microbiol 2009, 47:1543–1545
31. Yao JD, Germer JJ, Damond F, Roquebert B, Descamps D: Plasma
load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche
Cobas AmpliPrep/Cobas TaqMan HIV-1 assays. J Clin Microbiol
2008, 46:834; author reply 834
32. Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, Taylor N,
Eberle J: Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with
the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 2009,
47:1238 –1240
33. De Bel A, Marissens D, Debaisieux L, Liesnard C, Van den Wijngaert
S, Lauwers S, Pierard D: Correction of underquantification of human

Review of MID Assays
603
JMD November 2011, Vol. 13, No. 6

34.

35.
36.

37.

38.

39.

40.

41.

42.

43.

44.

45.

46.
47.

48.
49.
50.

51.

immunodeficiency virus type 1 load with the second version of the
Roche Cobas AmpliPrep/Cobas TaqMan assay. J Clin Microbiol
2010, 48:1337–1342
Sizmann D, Glaubitz J, Simon CO, Goedel S, Buergisser P, Drogan D,
Hesse M, Kroh M, Simmler P, Dewald M, Gilsdorf M, Fuerst M,
Ineichen R, Kirn A, Pasche P, Wang Z, Weisshaar S, Young K,
Haberhausen G, Babiel R: Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dualtarget approach. J Clin Virol 2010, 49:41– 46
Coleman WB, Tsongalis GJ: Molecular Diagnostics: For the Clinical
Laboratorian. Totowa, Humana Press, 2006
Elbeik T, Alvord WG, Trichavaroj R, de Souza M, Dewar R, Brown A,
Chernoff D, Michael NL, Nassos P, Hadley K, Ng VL: Comparative
analysis of HIV-1 viral load assays on subtype quantification: bayer
Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version
1.5. J Acquir Immune Defic Syndr 2002, 29:330 –339
Shafer RW, Jung DR, Betts BJ, Xi Y, Gonzales MJ: Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2000, 28:346 –348
Hirsch MS, Brun-Vézinet F, D’Aquila RT, Hammer SM, Johnson VA,
Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter
LM, Vella S, Jacobsen DM, Richman DD: Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA 2000, 283:2417–2426
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC; CPCRA 046 Study Team for the Terry Beirn
Community Programs for Clinical Research on AIDS: A randomized
study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000,
14:F83–F93
Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P,
Montagne N, Boucher CA, Schapiro JM, Dellamonica P: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999, 353:2195–2199
Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D,
Merigan TC, Efron B: HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous
protease inhibitor therapy had failed. Ann Intern Med 1999, 131:813–
821
Cunningham S, Ank B, Lewis D, Lu W, Wantman M, Dileanis JA,
Jackson JB, Palumbo P, Krogstad P, Eshleman SH: Performance of
the Applied Biosystems ViroSeq human immunodeficiency virus type
1 (HIV-1) genotyping system for sequence-based analysis of HIV-1 in
pediatric plasma samples. J Clin Microbiol 2001, 39:1254 –1257
Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B,
Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni
PG, Jacobsen DM, Richman DD: Antiretroviral drug resistance testing
in adult HIV-1 infection: 2008 recommendations of an International
AIDS Society-USA panel. Top HIV Med 2008, 16:266 –285
Shafer RW, Stevenson D, Chan B: Human immunodeficiency virus
reverse transcriptase and protease sequence database. Nucleic Acids Res 1999, 27:348 –352
Derdelinckx I, Van Laethem K, Maes B, Schrooten Y, De Schouwer K,
De Wit S, Fransen K, Garcia Ribas S, Moutschen M, Vaira D, Zissis G,
Van Ranst M, Van Wijngaerden E, Vandamme AM: Performance of
the VERSANT HIV-1 resistance assays (LiPA) for detecting drug
resistance in therapy-naive patients infected with different HIV-1 subtypes. FEMS Immunol Med Microbiol 2003, 39:119 –124
Workowski KA, Berman SM: Sexually transmitted diseases treatment
guidelines, 2006. MMWR Recomm Rep 2006, 55:1–94
Xu F, Markowitz LE, Gottlieb SL, Berman SM: Seroprevalence of
herpes simplex virus types 1 and 2 in pregnant women in the United
States. Am J Obstet Gynecol 2007, 43e1-43e6196:
Geretti AM, Brown DW: National survey of diagnostic services for
genital herpes. Sex Transm Infect 2005, 81:316 –317
Strick LB, Wald A: Diagnostics for herpes simplex virus: is PCR the
new gold standard? Mol Diagn Ther 2006, 10:17–28
Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer
AW, Carmeli Y: Comparison of mortality associated with methicillinresistant and methicillin-susceptible Staphylococcus aureus
bacteremia: a meta-analysis. Clin Infect Dis 2003, 36:53–59
American Thoracic Society; Infectious Diseases Society of America:
Guidelines for the management of adults with hospital-acquired, ven-

52.

53.

54.

55.

56.

57.

58.

59.

60.

61.

62.

63.

64.

65.

66.

tilator-associated, and healthcare-associated pneumonia. Am J
Respir Crit Care Med 2005, 171:388 – 416
Athanassa Z, Siempos II, Falagas ME: Impact of methicillin resistance
on mortality in Staphylococcus aureus VAP: a systematic review. Eur
Respir J 2008, 31:625– 632
Kelley PG, Grabsch EA, Howden BP, Gao W, Grayson ML: Comparison of the Xpert methicillin-resistant Staphylococcus aureus (MRSA)
assay, BD GeneOhm MRSA assay, and culture for detection of nasal
and cutaneous groin colonization by MRSA. J Clin Microbiol 2009,
47:3769 –3772
Wolk DM, Picton E, Johnson D, Davis T, Pancholi P, Ginocchio CC,
Finegold S, Welch DF, de Boer M, Fuller D, Solomon MC, Rogers B,
Mehta MS, Peterson LR: Multicenter evaluation of the Cepheid Xpert
methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid
screening method for detection of MRSA in nares. J Clin Microbiol
2009, 47:758 –764
Peterson LR, Liesenfeld O, Woods CW, Allen SD, Pombo D, Patel PA,
Mehta MS, Nicholson B, Fuller D, Onderdonk A: Multicenter evaluation of the LightCycler methicillin-resistant Staphylococcus aureus
(MRSA) advanced test as a rapid method for detection of MRSA in
nasal surveillance swabs. J Clin Microbiol 2010, 48:1661–1666
Francois P, Bento M, Renzi G, Harbarth S, Pittet D, Schrenzel J:
Evaluation of three molecular assays for rapid identification of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2007, 45:
2011–2013
Snyder JW, Munier GK, Heckman SA, Camp P, Overman TL: Failure
of the BD GeneOhm StaphSR assay for direct detection of methicillinresistant and methicillin-susceptible Staphylococcus aureus isolates
in positive blood cultures collected in the United States. J Clin Microbiol 2009, 47:3747–3748
Becker K, Pagnier I, Schuhen B, Wenzelburger F, Friedrich AW, Kipp
F, Peters G, von Eiff C: Does nasal cocolonization by methicillin-resistant coagulase-negative staphylococci and methicillin-susceptible
Staphylococcus aureus strains occur frequently enough to represent a
risk of false-positive methicillin-resistant S. aureus determinations by
molecular methods? J Clin Microbiol 2006, 44:229 –231
Gonzalez V, Padilla E, Gimenez M, Vilaplana C, Perez A, Fernandez
G, Quesada MD, Pallares MA, Ausina V: Rapid diagnosis of Staphylococcus aureus bacteremia using S. aureus PNA FISH. Eur J Clin
Microbiol Infect Dis 2004, 23:396 –398
Peters RP, Savelkoul PH, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CM, van Agtmael MA: Faster identification of pathogens in positive blood cultures by fluorescence in situ hybridization in
routine practice. J Clin Microbiol 2006, 44:119 –123
Peters RP, van Agtmael MA, Simoons-Smit AM, Danner SA, Vandenbroucke-Grauls CM, Savelkoul PH: Rapid identification of pathogens
in blood cultures with a modified fluorescence in situ hybridization
assay. J Clin Microbiol 2006, 44:4186 – 4188
Donnio PY, Fevrier F, Bifani P, Dehem M, Kervegant C, Wilhelm N,
Gautier-Lerestif AL, Lafforgue N, Cormier M, Le Coustumier A: Molecular and epidemiological evidence for spread of multiresistant
methicillin-susceptible Staphylococcus aureus strains in hospitals.
Antimicrob Agents Chemother 2007, 51:4342– 4350
Thomas L, van Hal S, O’Sullivan M, Kyme P, Iredell J: Failure of the BD
GeneOhm StaphS/R assay for identification of Australian methicillinresistant Staphylococcus aureus strains: duplex assays as the “gold
standard” in settings of unknown SCCmec epidemiology. J Clin Microbiol 2008, 46:4116 – 4117
Limbago BM, Long CM, Thompson AD, Killgore GE, Hannett GE,
Havill NL, Mickelson S, Lathrop S, Jones TF, Park MM, Harriman KH,
Gould LH, McDonald LC, Angulo FJ: Clostridium difficile strains from
community-associated infections. J Clin Microbiol 2009, 47:3004 –
3007
MacCannell D, Louie T, Rupnik M, Krulicki W, Armstrong G, Emery J,
Ward L, Lye T: Characterization of a novel TcdB-deficient NAP1
variant strain of Clostridium difficile. Presented at the 46th ICAAC
Conference, 2006 September 27–30, San Francisco, CA
Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC,
Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America;
Infectious Diseases Society of America: Clinical practice guidelines
for Clostridium difficile infection in adults: 2010 update by the Society
for Healthcare Epidemiology of America (SHEA) and the Infectious
Diseases Society of America (IDSA). Infect Control Hosp Epidemiol
2010, 31:431– 455

604
Emmadi et al
JMD November 2011, Vol. 13, No. 6

67. Pollock N, Westerling J, Sloutsky A: Specimen dilution increases the
diagnostic utility of the Gen-Probe Mycobacterium tuberculosis direct
test. Am J Clin Pathol 2006, 126:142–147
68. Mahony JB, Blackhouse G, Babwah J, Smieja M, Buracond S, Chong
S, Ciccotelli W, O’Shea T, Alnakhli D, Griffiths-Turner M, Goeree R:
Cost analysis of multiplex PCR testing for diagnosing respiratory virus
infections. J Clin Microbiol 2009, 47:2812–2817
69. Petti CA, Hillyard D: Value of RVP in clinical settings: older adults.
J Clin Virol 2007, 40(Suppl 1):S53–S54
70. Archimbaud C, Chambon M, Bailly JL, Petit I, Henquell C, Mirand A,
Aublet-Cuvelier B, Ughetto S, Beytout J, Clavelou P, Labbe A,
Philippe P, Schmidt J, Regagnon C, Traore O, Peigue-Lafeuille H:
Impact of rapid enterovirus molecular diagnosis on the management
of infants, children, and adults with aseptic meningitis. J Med Virol
2009, 81:42– 48
71. Hamilton MS, Jackson MA, Abel D: Clinical utility of polymerase chain
reaction testing for enteroviral meningitis. Pediatr Infect Dis J 1999,
18:533–537
72. Capaul SE, Gorgievski-Hrisoho M: Detection of enterovirus RNA in
cerebrospinal fluid (CSF) using NucliSens EasyQ Enterovirus assay.
J Clin Virol 2005, 32:236 –240
73. Ginocchio CC, Zhang F, Malhotra A, Manji R, Sillekens P, Foolen H,
Overdyk M, Peeters M: Development, technical performance, and
clinical evaluation of a NucliSens basic kit application for detection of
enterovirus RNA in cerebrospinal fluid. J Clin Microbiol 2005, 43:
2616 –2623
74. Kost CB, Rogers B, Oberste MS, Robinson C, Eaves BL, Leos K,
Danielson S, Satya M, Weir F, Nolte FS: Multicenter beta trial of the
GeneXpert enterovirus assay. J Clin Microbiol 2007, 45:1081–1086
75. Marlowe EM, Novak SM, Dunn JJ, Smith A, Cumpio J, Makalintal E,
Barnes D, Burchette RJ: Performance of the GeneXpert enterovirus
assay for detection of enteroviral RNA in cerebrospinal fluid. J Clin
Virol 2008, 43:110 –113
76. Mulford WS, Buller RS, Arens MQ, Storch GA: Correlation of cerebrospinal fluid (CSF) cell counts and elevated CSF protein levels with
enterovirus reverse transcription-PCR results in pediatric and adult
patients. J Clin Microbiol 2004, 42:4199 – 4203
77. Sefers SE, Raymer AK, Kilby JT, Persing DH, Tang YW: Prevalence
and management of invalid GeneXpert enterovirus results obtained
with cerebrospinal fluid samples: a 2-year study. J Clin Microbiol
2009, 47:3008 –3010
78. Shyamala V, Arcangel P, Cottrell J, Coit D, Medina-Selby A, McCoin
C, Madriaga D, Chien D, Phelps B: Assessment of the target-capture
PCR hepatitis B virus (HBV) DNA quantitative assay and comparison
with commercial HBV DNA quantitative assays. J Clin Microbiol 2004,
42:5199 –5204
79. Valsamakis A: Molecular testing in the diagnosis and management of
chronic hepatitis B. Clin Microbiol Rev 2007, 20:426 – 439
80. Cox AL, Netski DM, Mosbruger T, Sherman SG, Strathdee S, Ompad
D, Vlahov D, Chien D, Shyamala V, Ray SC, Thomas DL: Prospective
evaluation of community-acquired acute-phase hepatitis C virus infection. Clin Infect Dis 2005, 40:951–958

81. Poordad FF: Review article: the role of rapid virological response in
determining treatment duration for chronic hepatitis C. Aliment Pharmacol Ther 2010, 31:1251–1267
82. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht
J: Early virologic response to treatment with peginterferon alfa-2b
plus ribavirin in patients with chronic hepatitis C. Hepatology 2003,
38:645– 652
83. Ghany MG, Strader DB, Thomas DL, Seeff LB: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009,
49:1335–1374
84. Forman MS, Valsamakis A: Performance characteristics of a quantitative hepatitis C virus RNA assay using COBAS AmpliPrep total
nucleic acid isolation and COBAS taqman hepatitis C virus analytespecific reagent. J Mol Diagn 2008, 10:147–153
85. Han JH, Shyamala V, Richman KH, Brauer MJ, Irvine B, Urdea MS,
Tekamp-Olson P, Kuo G, Choo QL, Houghton M: Characterization of
the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5= untranslated region and poly(A) tails at
the 3= end. Proc Natl Acad Sci U S A 1991, 88:1711–1715
86. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C:
Differences between two real-time PCR-based hepatitis C virus (HCV)
assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and
one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008, 46:3880 –3891
87. Verani JR, McGee L, Schrag SJ; Division of Bacterial Diseases,
National Center for Immunization and Respiratory Diseases, Centers
for Disease Control and Prevention (CDC): Prevention of perinatal
group B streptococcal disease: revised guidelines from CDC, 2010.
MMWR Recomm Rep 2010, 59(RR-10):1–36
88. Bergeron MG, Ke D: New DNA-based PCR approaches for rapid
real-time detection and prevention of group B streptococcal infections in
newborns and pregnant women. Expert Rev Mol Med 2001, 3:1–14
89. Forrest GN, Mehta S, Weekes E, Lincalis DP, Johnson JK, Venezia
RA: Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother
2006, 58:154 –158
90. Peleg AY, Tilahun Y, Fiandaca MJ, D’Agata EM, Venkataraman L,
Moellering RC Jr, Eliopoulos GM: Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and
Pseudomonas aeruginosa. J Clin Microbiol 2009, 47:830 – 832
91. Shepard JR, Addison RM, Alexander BD, Della-Latta P, Gherna M,
Haase G, Hall G, Johnson JK, Merz WG, Peltroche-Llacsahuanga H,
Stender H, Venezia RA, Wilson D, Procop GW, Wu F, Fiandaca MJ:
Multicenter evaluation of the Candida albicans/Candida glabrata
peptide nucleic acid fluorescent in situ hybridization method for
simultaneous dual-color identification of C. albicans and C. glabrata
directly from blood culture bottles. J Clin Microbiol 2008, 46:50 –55
92. Wilson DA, Joyce MJ, Hall LS, Reller LB, Roberts GD, Hall GS,
Alexander BD, Procop GW: Multicenter evaluation of a Candida albicans peptide nucleic acid fluorescent in situ hybridization probe for
characterization of yeast isolates from blood cultures. J Clin Microbiol
2005, 43:2909 –2912

